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PI3K  Isoform  Dependence  and  Translational  Regulation  of  c-MYC  in  PTEN-
deficient Leukemia 
 
  ABSTRCT   
 
           T-cell acute lymphoblastic leukemia (T-ALL) is a lethal decrease that is usually 
caused by hyper-activation of PI3K signaling, generally featured with loss of Pten. In this 
thesis, using genetically engineered murine model of T-ALL initiated by Pten-loss, we 
studied the roles of different PI3K catalytic subunit isoforms in T cell specific PTEN null 
induced  T-ALL.  We  show  that  neither  p110α  nor  p110β  isoform  is  critical  for  the 
maintenance  of  the  T  cell  specific  PTEN  loss  induced  T-ALL,  suggesting  potential 
critical role of the PI3K p110δ and p110γ in PTEN-null induced T-ALL. 
 
           Highly elevated c-MYC oncoprotein abundance is found in most cases of T-cell 
acute lymphoblastic leukemia (T-ALL) and plays a key pathogenic role in this disease. 
Notably, the co-occurrence of c-MYC overexpression and PTEN-deficiency is common 
in T-cell acute lymphoblastic leukemia (T-ALL). However, the mechanistic link between 
the  two  events  resulting  in  this  correlation  has  remained  unclear  and  unexploited 
therapeutically. Using the genetically engineered murine model of T-ALL initiated by 
Pten-loss  and  featuring  spontaneous  overexpression  of  c-MYC  as  well  as  a  panel  of 
PTEN-deficient c-MYC-high human T-ALL cell lines, we found that the abundance of c-  iv 
MYC  in  these  cells  is  critically  dependent  on  hyper-activation  of  PI3K-mTOR-S6K1 
signaling. While multiple mechanisms have been proposed to allow PI3K signaling to 
regulate c-MYC expression, we found that the details of c-MYC regulation in T-ALL are 
unique, not occurring via the regulation of c-MYC stability by phosphorylation or the 
common  translational  initiation  machinery  via  eIF4E.  We  demonstrate  that  the  PI3K 
signaling  pathway  robustly  regulates  translation  of  MYC  via  eIF4A,  a  eukaryotic 
translation  initiation  factor  with  intrinsic  RNA  helicase  activity.  Notably,  eIF4A 
inhibition, either by RNA interference or via the pharmacological inhibitor hippuristanol, 
efficiently  suppresses  MYC  translation  and  tumor  cell  proliferation  via  a  mechanism 
specifically dependent on the 5’UTR of c-MYC. Our study establishes a novel eIF4A-
dependent mechanism of MYC translation essential in T-ALL, and identifies eIF4A as a 
promising therapeutic target in c-MYC-dependent hematological malignancies. 
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1.1 T Cell Lymphoma and T cell acute lymphoblastic leukemia 
 
1.1.1  T Cell Lymphoma 
 
Lymphoma  is  the  most  common  blood  cancer  type.  There  are  two  main  types  of 
lymphoma:  the  Hodgkin  lymphoma  and  the  non-Hodgkin  lymphoma.  Non-Hodgkin 
lymphoma  accounts  for  more  than  90%  of  all  of  the  lymphoma  cases.  Lymphoma 
happens when cells of the immune system, called lymphocytes, grow out of control. 
There are two types of lymphocytes and thus two types of non-Hodgkin lymphomas, the 
B  cell  lymphoma  and  T  cell  lymphoma.  T  cell  lymphoma  usually  originates  in  the 
thymus where the T cells develop and mature and then spread to peripheral lymphoid 
organs including the spleen and the lymph nodes (Hagenbeek and Spits, 2008). Typically, 
it appears as a solid tumor of transformed lymphoblasts, featured with enlarged nuclei. T 
cell lymphoma is less common than B cell lymphoma. It accounts for about 15% of non-
Hodgkin lymphomas in the United States and it is more common in Asia. However, T 
cell lymphoma is a lethal disease and it has poor prognosis compared to B cell lymphoma 
(Tsukasaki  et  al.,  2014).  There  is  currently  no  targeted  therapy  available  for  T  cell 
lymphoma.  The  commonly  used  therapy  strategies  include  surgery,  radiation, 
transplantation, and chemotherapy. 
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1.1.2  T Cell Acute Lymphoblastic Leukemia (T-ALL) 
 
Since transformed T lymphocytes migrate via circulation, they usually cause leukemia 
featured  with  high  white  blood  cell  count  and  spread  of  lymphoblasts  in  the  bone 
marrow. Due to the lymphoblastic origin and quick development of this type of leukemia, 
it is usually called as T cell acute lymphoblastic leukemia (T-ALL). T-ALL accounts for 
about 15% of pediatric cases and 20% of adults cases of acute leukemia (Ravandi et al., 
2005). It is most often seen in children and adolescents. T-ALL is also a lethal disease. 
There  is  no  targeted  therapy  for  this  disease.  Commonly  used  therapies  for  T-ALL 
include chemotherapy, radiation and transplantation (Veigaard et al., 2014). Genetically, 
T-ALL  is  commonly  featured  with  various  genetic  translocations  due  to  the  active 
recombination  process  of  T  cells  during  development.  The  mostly  hyper-activated 
signaling pathways in T-ALL include the Notch signaling (accounts for about 50% of the 
T-ALL patients) (Pear and Aster, 2004) and the PI3K signaling (accounts for about 40% 
of the T-ALL patients) (Gutierrez et al., 2009). 
 
1.2 PI3K Signaling and PI3K Catalytic Subunit Isoforms 
 
1.2.1 PI3K Signaling 
 
PI3K signaling pathway is one of the most frequently deregulated signaling pathways in 
various  human  cancers.  As  major  effectors  for  extracellular  stimuli,  PI3Ks  transduce 
signals  by  phosphorylating  the  3’  position  on  phosphatidylinositol-4,5-bisphosphate   4 
yielding  phosphatidylinositol-3,4,5-trisphosphate  (Engelman,  2009;  Liu  et  al.,  2009b). 
This process can be antagonized by the phosphatase PTEN, the main suppressor of PI3K 
signaling. Activation of PI3Ks will phosphorylate and thus activate the serine-threonine 
kinase AKT, the main downstream effector of PI3K, which will further activate multiple 
downstream pathways (Wong et al., 2010). The main downstream effecter of AKT is the 
mTOR complex1 (mTORC1), which in turn can activate its downstream S6 Kinase1 
(S6K1) and phosphorylate the translation initiation factor 4E-binding protein1 (4EBP1), 
resulting in its dissociation from the translation initiation factor eIF4E and activation of 
cap-dependent  translation  initiation.  Various  downstream  effectors  of  AKT  can 
collectively  promote  cell  growth,  survival,  and  metabolism.  Hyperactivation  of  PI3K 
signaling can stimulate multiple downstream signaling effects that collectively lead to 
oncogenesis (Engelman, 2009).   5 
 
 
Figure 1.1 PI3K Signaling. PI3K Signaling is activated by receptor tyrosine kinases 
(RTKs), GPCR or Ras. Activation of PI3K leads to phosphorylation of PIP2 into PIP3, 
which further activates its downstream kinase AKT. AKT activation further activates 
multiple downstream effectors and the main one is the mTORC1 complex. mTORC1 
phosphorylate S6K1 to activate its downstream signaling or phsophorylate 4EBP1 and 
thus activate translation initiation. 
 
1.2.2  PI3K Catalytic Subunit Isoforms 
 
There are three classes of PI3Ks of which the Class I PI3Ks are the most implicated class   6 
in  human  cancers  (Ilic  and  Roberts,  2010).  Class  I  PI3Ks  are  responsible  for  the 
production  of  Phosphatidylinositol  3-phosphate  (PI(3)P),  Phosphatidylinositol  (3,4)-
bisphosphate  (PI(3,4)P2),  and  Phosphatidylinositol  (3,4,5)-trisphosphate  (PI(3,4,5)P3). 
Class I PI3Ks are composed of a regulatory and a catalytic subunit. For Class IA PI3K, it 
is composed of a heterodimer of a p85 regulatory subunit and a p110 catalytic subunit. 
There are three variants of the p110 catalytic subunit named p110α, p110β, or p110δ 
catalytic subunit. The p110α and p110β subunits are expressed in all cells while p110δ is 
expressed primarily in leukocytes. The class IB PI3K is composed by the regulatory p101 
and catalytic p110γ subunits (Liu et al., 2009a). It was long thought that different PI3K 
catalytic subunits have similar functions until recent studies suggest that the roles and 
involvement of different PI3K catalytic subunits in various models for tumorigenesis and 
maintenance. For example, in a prostate specific PTEN-Null driven cancer model, p110β, 
but not p110α was shown to be critical for tumor maintenance (Jia et al., 2008). In breast 
cancer  driven  by  polyoma  middle  T  antigen  (MT)  or  HER2/Neu  transgenic  models, 
depletion of p110α blocked tumorigenesis. Surprisingly, p110β ablation resulted in the 
increase  of  tumorigenesis  (Utermark  et  al.,  2012).  Another  example  is  that  p110α  is 
responsible for the sustained survival of suprabasal cells of the epidermis in the absence 
of  PTEN,  p110β  is  important  for  the  hyperproliferation  of  basal  cells  in  PTEN 
hamartoma tumor syndrome (Wang et al., 2013). All these studies indicate the distinct 
roles of PI3K catalytic subunits in tumorigenesis under various genetic conditions and 
demonstrate the significance to study PI3K catalytic subunit isoform specificity for more 
effective and precise targeting of PI3Ks in human cancers. 
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                                                                                             (Klaus Okkenhaug et al., 2003) 
 
Figure 1.2 PI3K Catalytic Subunit Isoforms. Class IA PI3K has three catalytic subunit 
isoforms, p110α, p110β, or p110δ. Class IB PI3K has one catalytic subunit isoform, 
p110γ. 
 
1.3 PI3K Signaling in T-ALL 
 
PI3K signaling has been reported to be frequently deregulated in T cell lymphoma and 
leukemia (Gutierrez et al., 2009). Mutation of PIK3CA and AKT; deletion and mutation 
of  PTEN  have  been  identified  in  more  than  40%  of  human  T  cell  lymphoma  and 
leukemia samples (Gutierrez et al., 2009). Both T cell specific PTEN knockout mice and 
mice expressing constitutively activated AKT develop T cell lymphoma and leukemia 
with short latency (Hagenbeek and Spits, 2008; Kharas et al., 2010), strongly suggesting 
that the PTEN-PI3K-AKT axis can play a critical role in T cell lymphoma and leukemia. 
Also, multiple small molecule inhibitors of PI3K signaling have also been shown to be 
able to inhibit the proliferation of human T cell lymphoma/leukemia cell lines in vitro, 
indicating  potential  therapeutic  effects  of  PI3K  inhibitors  for  the  treatment  of  T  cell 
lymphoma/leukemia (Chiarini et al., 2009; Chiarini et al., 2010; Evangelisti et al., 2011). 
However, little is known about the isoform specificity of PI3K catalytic subunit isoforms   8 
in T-ALL. It is unclear whether targeting specific PI3K isoform is enough to block T-
ALL driven by PTEN-null deficient cancers and if yes, which isoform(s) would be. It is 
also  unclear  how  PI3K  signaling  activates  downstream  effectors  and  thus  cause 
oncogenesis in T-ALL. 
 
1.4 PI3Ks Functions in T cells  
 
As  one  of  the  signaling  pathways  critical  for  multiple  cellular  functions,  various 
components of PI3K signaling have been reported to be important for the development of 
T  cells.  T  cell  specific  knock-out  mice  models  of  AKT1/2  and  PDK1  showed  much 
smaller thymus compared to the wide type mice with blockage of T cell development 
from the DN3 to DN4 stage (Hinton et al., 2004; Juntilla et al., 2007). The functions of 
PI3K catalytic subunits in T cells also have been previously conducted, especially p110δ 
and p110γ, the two isoforms specifically expressed in leukocytes. Mice deficient in both 
p110γ and p110δ have a profound block in T cell development that occurs at the beta-
selection checkpoint. pre-TCR-induced signaling is also greatly reduced in p110gamma-
/-p110delta-/- thymocytes (Webb et al., 2005). Specifically, mice lacking expression of 
the PI3K p110γ subunit have a partial defect in T cell differentiation, which is restored 
after  expression  of  an  active  PI3K  mutant  (Rodriguez-Borlado  et  al.,  2003).  p110γ  -
deficient  T  cells  show  reduced  chemotactic  responses  to  the  lymphoid  chemokines 
including CCL19, CCL21, and CXCL12 (Reif et al., 2004). p110γ is dispensable for 
constitutive migration of naive CD8 T cells and subsequent activation and differentiation 
into effector CD8 T cells, but plays a central role in the migration of effector CD8 T cells   9 
into inflammatory sites (Martin et al., 2008). The Ras-p110γ interaction was also reported 
to  be  necessary  for  efficient  β-selection-promoted  proliferation  of  T  cells  (Janas  and 
Turner,  2011).  Dominant-activating  germline  mutations  in  p110δ  result  in  T  cell 
senescence  and  human  immunodeficiency  (Lucas  et  al.,  2014).  Antigen  receptor 
signaling in T cells is impaired and immune responses in vivo are decreased in p110δ 
mutant mice (Okkenhaug et al., 2002). Specifically, p110δ mutant mice have attenuated 
function  of  CD4+CD25+Foxp3+  regulatory  T  cells  (Tregs)  featured  with  lower 
suppressor function in vitro and failed secretion of cytokines (Patton et al., 2006). p110δ 
has also been reported to promote Th17 differentiation in recent studies (Steinbach et al., 
2014).  On the other hand, the roles of p110α and p110β in normal T cell development 
and function are much less studied. Our unpublished data suggest that T cell specific 
p110α deletion caused in a much smaller thymus whereas p110β deletion is dispensable 
for T cell development. 
 
1.5  c-MYC and Therapy for the c-MYC Oncoprotein 
 
1.5.1 The c-MYC Oncoprotein 
 
c-Myc  is  a  basic-helix-loop-helix  leucine  zipper  (bHLH-LZ)  transcription  factor  that 
functions as a master regulator of the transcriptome (Lin et al., 2012b; Nie et al., 2012), 
thus governing many cellular processes, including cell proliferation and transformation. 
A wide spectrum of genomic and genetic alterations of MYC have been found in various 
tumors, including gene translocations, amplification, overexpression and occasional point   10 
mutations (Beroukhim et al., 2010; Eilers and Eisenman, 2008; Meyer and Penn, 2008; 
Pomerantz et al., 2009; Setoodeh et al., 2013; Wright et al., 2010). In addition, increased 
abundance  of  the  c-MYC  protein  is  also  frequently  observed  in  cancer  via  distinct 
mechanisms such as alterations in upstream regulators or posttranslational modifications 
(Choi et al., 2010; Huang et al., 2004; Malempati et al., 2006; Wiegering et al., 2013). 
The upregulation of c-MYC occurs in a majority of human malignancies, and is usually 
associated with poor prognosis (Miyawaki et al., 2012; Pedersen et al., 2013; Ryan et al., 
2012). Therefore, c-MYC represents a major target for human cancer therapy. 
 
1.5.2 Targeted therapy for the c-MYC Oncoprotein 
 
Despite decades of enormous effort to develop therapeutics to inhibit its function, direct 
targeting c-MYC via pharmacological agents has remained challenging, in part due to the 
fact  that  the  c-MYC  protein  lacks  a  conventional  druggable  pocket  (Darnell,  2002). 
Although it is known that the oncogenic activity of c-MYC requires dimerization with its 
binding  partner  MAX  (Amati  et  al.,  1993;  Blackwood  and  Eisenman,  1991),  efforts 
trying to inhibit such protein-protein interaction have also been unsuccessful (Nair and 
Burley,  2003).  Therefore,  c-MYC  protein  is  long  thought  to  be  undruggable.  Recent 
studies  demonstrated  the  existence  of  synthetic  lethal  interactions  between  c-MYC 
activation  and  certain  elements  in  a  number  of  cellular  pathways,  such  as  protein 
sumorylation  (Kessler  et  al.,  2012),  cell  division  (Horiuchi  et  al.,  2012;  Yang  et  al., 
2010),  and  initiation  of  protein  translation  (Lin  et  al.,  2012a),  suggesting  potential 
strategies to target c-MYC via inhibition of proteins critical for its function. In addition,   11 
pharmaceutically targeting BET bromodomain proteins has been shown to effectively 
suppress MYC transcription, and consequently, the growth of some classes of c-MYC 
dependent tumors (Bandukwala et al., 2012; Cheng et al., 2013; Da Costa et al., 2013; 
Delmore et al., 2011; Henssen et al., 2013; Lockwood et al., 2012; Mertz et al., 2011; Ott 
et  al.,  2012;  Shimamura  et  al.,  2013;  Tolani  et  al.,  2013;  Zuber  et  al.,  2011).  These 
findings  have  underscored  the  potential  of  indirectly  targeting  c-MYC  through 
intervening in the molecular mechanisms that critical regulate c-MYC expression. 
 
1.6  c-MYC in T-ALL 
 
The Myc-TCRA translocation has been discovered in many human T cell lymphoma 
patients. Overexpression of the c-MYC protein is also frequent in various human T-ALL 
cell lines. Myc was identified as a critical downstream target of Notch1 signaling in T-
ALL (Palomero et al., 2006). It was found to be widely elevated in several Pten null T 
cell lymphoma/leukemia mouse models (Guo et al., 2008; Liu et al., 2010; Zhang et al., 
2011). Further investigations have verified the Myc-TCRA translocation and knock out 
of  c-Myc  in  the  hematopoietic  system  was  able  to  significantly  postpone  T  cell 
lymphomagenesis in Pten null mice (Zhang et al., 2011), suggesting that Myc may be 
critical for Pten null T cell lymphoma/leukemia. However, it is unclear whether this is 
purely due to additive oncogenic effects of the two lesions or to a more fundamental 
molecular connection between PI3K signaling and the c-Myc oncogene. If it is the latter, 
how these two oncogenic events are correlated and what would be the clinical relevance 
of the regulation is unknown.   12 
1.7 c-MYC 5’UTR (5’ Untranslatated Region) and RNA Helicases 
 
The 5’ UTR of c-MYC has an internal ribosome entry segment (IRES) featured with 
secondary  structure  (Stoneley  et  al.,  1998).  Cellular  IRESes  have  been  reported  in 
multiple mRNAs critical for cell growth and proliferation. These genes usually function 
as  oncogenes,  such  as  CyclinD1  and  c-Jun  (Shi  et  al.,  2005).  Previous  studies  have 
suggested that the 5’UTR of c-MYC, similar to viral IRESes, may initiate translation in a 
cap-independent manner.  Highly structured c-MYC 5’UTR can impede the binding and 
movement of the 40S ribosome. Therefore, the unwinding of c-MYC 5’UTR by RNA 
helicases are critical to expose the cellular IRES and thus initiate translation (Carter et al., 
1999). On the other hand, it is unknown how the 5’UTR of c-MYC is regulated by 
upstream signaling and what is (are) the RNA helicase(s) that can unwire c-MYC 5’UTR 
and  thus  initiate  translation.  Multiple  RNA  helicases  have  been  studied  in  various 
systems.  The  mostly  reported  RNA  helicase  is  eukaryotic  translation  initiation  factor 
eIF4A (also named as DDX2) (Parsyan et al., 2011). Together with its accessory proteins 
including eIF4B and eIF4H, eIF4A is thought to unwind structured mRNAs. Growing 
recent evidence also suggested that other DEAD-BOX RNA helicases such as DHX9, 
DHX29,  are  also  important  for  translation  initiation  and  may  promote  the  scanning 
processivity of the 40S subunit. They either function alone or can synergize with eIF4A 
to facilitate translation initiation of certain mRNAs (Parsyan et al., 2011). So far, there is 
lack of ribosome profiling studies to identify targets of eIF4A. Given that c-MYC 5’UTR 
is highly structured, it is likely that c-MYC is one of the targets of eIF4A. 
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Summary 
 
Both the PI3K signaling and the c-MYC oncogene have been identified as critical lesions 
in T-ALL, demonstrating the promising potential to targets these two oncogenic nodes 
for efficient targeted therapy in human cancers. Given the fact that T-ALL is lethal and 
currently no targeted therapy is available for T-ALL, there is urgent need to understand 
how PI3K signaling drives oncogenesis in T-ALL for more effective targeting of the 
signaling and also to test whether there would be isoform specificity of the enzyme and 
thus been utilized to design isoform specific inhibitors. In addition, as one of the mostly 
hyper-activated oncogenes in various human cancers, c-MYC presents a promising target 
for  effective  therapy  in  more  than  70%  of  human  cancers  dependent  on  c-MYC. 
However, due to the difficulty to target transcription factors, c-MYC has long thought to 
be undruggable until recent discoveries of bromo domain inhibitors. Given the fact that c-
MYC is spontaneously widely elevated in PTEN null driven T-ALL, it is intriguing to 
hypothesize that there could be clinically relevant regulatory mechanisms of c-MYC by 
the PI3K signaling pathway and thus could be utilized for novel strategy to target c-MYC 
dependent  human  cancers.  In  this  thesis,  we  are  mainly  interested  to  address  two 
questions.  First,  whether  there  is  any  isoform  specificity  of  PI3K  catalytic  subunit 
isoforms and if yes, what isoform(s) is (are) critical for PTEN null driven T-ALL and 
second, whether there is any mechanistic correlation between the PI3K signaling and c-
MYC oncogene. If yes, whether it could be utilized to discover novel strategy to target 
the currently undruggable c-MYC oncogene is unclear. 
   14 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
PI3K Catalytic Subunit Isoform Specificity in PTEN-deficient T-ALL 
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Introduction 
 
As  one  of  the  most  frequently  hyperactivated  signaling  pathways  in  various  human 
cancers, PI3K signaling presents a very intriguing signaling pathway for targeted cancer 
therapy (Liu et al., 2009b). The PI3K is composed of a regulatory p85 subunit and a 
catalytic p110 subunit. There are different catalytic subunit isoforms of PI3Ks in various 
human cancers, including the p110α, p110β, p110δ and p110γ isoforms (Fritsch and 
Downward,  2013),  each  is  capable  to  regulate  distinct  biological  functions  in  cell 
signaling and tumorigenesis. Recent interest has drawn to study the function of isoform 
specificity for more effective targeting of the PI3K signaling in human cancers. Given 
our previous studies in other cancer systems demonstrating the critical roles of the p110α 
or p110β isoforms in tumorigenesis and tumor maintenance (Utermark et al., 2012; Wang 
et al., 2013), we used a T cell specific PTEN null mice model (Lck+ Pten-/-) to check 
whether the p110α and/or p110β isoforms is critical for PTEN null induced T-ALL. 
 
Contributions: Dr. Thomas Roberts and I designed the project and experiments together. I 
performed most of the experiments described in this chapter. Other peoples’ contribution 
is stated in the thesis.  
 
Results 
 
p110α Loss Fails to Block T Cell Lymphoma Driven By Pten Loss  
   16 
To start, we first tested whether knocking out the PI3K p110α isoform in PTEN null 
leukemia  can  block  tumorigenesis,  since  p110α  is  the  isoform  mostly  reported  to  be 
critical for PI3K signaling during tumorigenesis. FPA f/+ or FPA f/f mice were crossed to 
Lck+ Pten-/- mice to generate one allele or two alleles deletion of PIK3CA (Lck+ FPA+/- 
Pten-/- mice and Lck+ FPA-/- Pten-/- mice). Interestingly, deletion of neither one allele 
nor both alleles of PIK3CA did not postpone oncogenesis latency or decrease penetration 
rate of Lck+ Pten-/- mice (Fig 2.1), suggesting that p110α may not be critical for the 
maintenance of PTEN-null T-ALL. 
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A 
 
B 
Genotype  Number  Latency  Penetration 
Lck+ PTEN-/-  20  112  100% 
Lck+ FPA+/- PTEN-/-  15  116  100% 
Lck+ FPA-/- PTEN-/-  14  117  100% 
  
Figure 2.1 p110α loss fails to block T cell lymphoma driven by Pten loss  
 
(A) Kaplan-Meier survival curve for Lck+ PTEN-/- mice (red), Lck+ FPA +/- PTEN-/- 
(yellow) mice, Lck+ FPA-/- PTEN-/- (green) and
 control Lck+
 mice (black). 
 
(B) Summary of survival conditions for Lck+PTEN-/-, Lck+ FPA+/- PTEN-/- and Lck+ 
FPA-/- PTEN-/- mice. 
 
Contributions: I performed all the experiments for this figure.   18 
p110β Loss Fails to Block T Cell Lymphoma Driven By Pten Loss  
 
We then tested whether p110β can block tumorigenesis in Pten null driven T-ALL. FPB 
f/+ or FPB f/f mice were crossed to Lck+ Pten-/- mice to generate one allele or two 
alleles deletion of PIK3CB (Lck+ FPB+/- Pten-/- mice and Lck+ FPB-/- Pten-/- mice). 
To our surprise, deletion of neither one allele nor both alleles of PIK3CB also did not of 
Lck+  Pten-/-  mice  (Fig  2.2),  suggesting  that  p110β  may  also  not  be  critical  for  the 
maintenance of PTEN-null T-ALL. 
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A 
 
 
B 
Genotype  Number  Latency  Penetration 
Lck+PTEN-/-  20  112  100% 
Lck+ FPB+/- PTEN-/-  12  101  100% 
Lck+ FPB-/- PTEN-/-  9  120  100% 
  
Figure 2.2 p110β loss fails to block T cell lymphoma driven by Pten loss  
 
(A) Kaplan-Meier survival curve for Lck+ PTEN-/- mice (red), Lck+ FPB +/- PTEN-/- 
(yellow) mice, Lck+ FPB-/- PTEN-/- (green) and
 control Lck+
 mice (black). 
 
(B) Summary of survival conditions for Lck+PTEN-/- mice, Lck+ FPB+/- PTEN-/- mice 
and Lck+ FPB-/- PTEN-/- mice. 
 
Contributions: I performed all the experiments in this figure.   20 
p110α or p110β Deleted Pten Null Mice Have Similar Phenotype as Pten Null Mice 
 
To test whether p110α or p110β deletion may change the phenotype of Pten null driven 
T-ALL,  we  first  measured  the  organ  weight  of  moribund  mice  from  various  genetic 
backgrounds.  Consistent  with  survival  data,  the  organ  weights  of  different  genetic 
backgrounds  don’t  show  statistic  difference  (Fig  2.3).  We  also  confirmed  similar 
phenotype  via  HE  staining  demonstrating  the  invasion  of  lymphblasts  invading  into 
various organs of the immune system (Fig 2.4). 
 
To further confirm similar phenotype of mice from different background, we confirmed 
the elevation of white blood cell counts in various genetic backgrounds (Fig 2.5). They 
also showed expansion and invasion of DP (CD4+CD8+) cells or SP4 (CD4+CD8-) cells 
in the thymus, lymph nodes, bone marrow and spleen (Fig 2.6A), with highly increased 
percentage of activated T cells (CD5+ TCR+) and loss of B cells (CD19+) in the lymph 
nodes,  bone  marrow  and  spleen  of  moribund  mice.  All  these  data  collectively 
demonstrate that the T-ALL developed in Lck+ FPB+/- PTEN-/- mice and Lck+ FPB-/- 
PTEN-/- mice is similar to Lck+ PTEN-/- mice, suggesting that neither p110α nor p110β 
is critical for Pten null induced T-ALL. 
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A                                                            B                  
C D  
 
 
Figure 2.3 p110α and p110β deleted Pten null mice also have enlarged organs 
Lymph node (A), Spleen (B), Thymus (C) and Liver (D) weight of control Lck+ mice, 
Lck+ PTEN-/- mice, Lck+ FPA +/- PTEN-/- mice, Lck+ FPA-/- PTEN-/- mice, Lck+ 
FPB+/- PTEN-/- mice and Lck+FPB-/- PTEN-/- mice. 
 
Contributions: I performed all the experiments for this figure.   22 
Figure 2.4 Lck+ Pten-/- FPA-/- mice and Lck+ Pten-/- FPB-/- mice showed similar 
HE staining phenotype compared to Lck+ Pten-/- mice. 
 
Representative H&E-stained primary thymus (A), lymph nodes (B), and spleen sections 
(C) and representative Wright-giemsa stained primary bone marrow cytospin sections (D) 
from moribund Lck+ Pten-/- mice, Lck+ Pten-/- FPA-/- mice, Lck+ Pten-/- FPB-/- mice 
and age controlled Lck- Ptenf/f mice. 
 
Contributions: I performed all the experiments for this figure. 
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Figure 2.4 (Continued) 
A 
 
B 
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Figure 2.4 (Continued) 
C 
 
D 
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Figure 2.5 Lck+ Pten-/- FPA-/- mice and Lck+ Pten-/- FPB-/- mice showed similar 
white blood cell counts compared to Lck+ Pten-/- mice. 
 
Contributions: I performed all the experiments in this figure. 
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Figure 2.6 Lck+ Pten-/- FPA-/- mice and Lck+ Pten-/- FPB-/- mice showed similar 
FACS staining pattern compared to Lck+ Pten-/- mice. 
 
Expansion and invasion of DP or SP4 cells (A), CD5+ activated T cells (B) and loss of 
CD19+ B cells (C) in the thymus, lymph nodes, spleen and bone marrow of Lck+ Pten-/- 
FPA-/- mice, Lck+ Pten-/- FPB-/- mice and Lck+ Pten-/- mice. 
 
Contributions: I performed all the experiments for this figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   27 
Figure 2.6 (Continued) 
 
A 
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Figure 2.6 (Continued) 
 
B 
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Figure 2.6 (Continued) 
 
C 
 
Contributions: I performed all the experiments for this figure. 
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Discussion and Future Directions 
 
It  was  a  surprise  that  neither  p110α  nor  p110β  affects  tumorigenesis  and  tumor 
maintenance of PTEN null induced T-ALL given the fact that either or both of them are 
critical for PTEN null tumors in other systems. As we were doing the study, one paper 
published in 2012 in the journal of Cancer Cell stating that non-classical isoforms of 
PI3K, including the p110δ and p110γ, are critical for the maintenance of PTEN null T-
ALL. In this study, they also used Lck+ PTEN-/- mice as the model system and showed 
that deletion of both p110δ and p110γ block tumorigenesis (Figure 2.7). This study also 
used  a  small  molecule  inhibitor  CAL-130,  a  dual  inhibitor  of  p110δ  and  p110γ,  and 
showed effective inhibition of tumor growth in vivo, indicating the efficiency of blocking 
p110δ and p110γ to inhibit PTEN null induced T-ALL (Figure 2.8). 
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Figure 2.7 Kaplan-Meier survival curve for Lck+ PTEN-/- mice (black), Lck+ FPD-/- 
PTEN-/- (blue) mice, Lck+ FPG-/- PTEN-/- (grey), and triple knock out (TKO) mice. (P. 
Subramaniam et al., 2012) 
 
 
 
Figure 2.8 Phenotypic analyses of thymus from mice treated with either CAL-130 (10 mg 
kg
-1 every 8 hr) or vehicle control for 7 days. (P. Subramaniam et al., 2012)   32 
 
It is very interesting that p110δ and p110γ are critical for PTEN null driven T-ALL, since 
it is different from other PTEN null driven cancers commonly featured with critical roles 
of  p110α  and  p110β.  One  potential  explanation  is  that  p110δ  and  p110γ  are  mostly 
expressed in leucocytes, including B cells and T cells. The results from our study and 
others indicate that in the absence of PTEN-mediated regulation, distinct class I PI3K can 
predominate in the development and survival of tumors in a manner that is most likely to 
involve isoforms that normally play a critical role in the function of that particular cell 
type. Given the possibility of potential toxicities that would be associated with pan-PI3K 
inhibitor or AKT inhibitors, the inhibition of p110δ and p110γ would be more specific.  
 
Recent studies have also shown the existence of a complex signaling system involving 
PI3K  signaling  between  the  leukemic  cells  and  stroma  cells  in  the  tumor 
microenvironment (Ayala et al., 2009; Konopleva et al., 2009; Burger et al., 2009). This 
is also supported by the recent studies that the PI3K p110δ inhibitor CAL-101 reduces 
levels of circulating chemokines known to be critical for tissue localization of chronic 
lymphocytic leukemic (CLL) cells (Hoellenriegel et al., 2011). Therefore, the study of 
PI3K isoforms may also contribute to the study of micro-environmental interactions via 
the PI3K signaling in T-ALL as well. 
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Experimental Procedures 
 
Mice 
 
Lck+ (Hennet et al., 1995) and PTEN f/f (Lesche et al., 2002) mice were crossed
 to 
generate  Lck+  PTEN  f/f  mice  for  this  study.  PIK3CA  f/f  mice,  PIK3CA  f/+  mice, 
PIK3CB f/f mice and PIK3CB f/+ mice were crossed with Lck+ PTEN f/f to generate 
various genetic background mice for this study. All animals were housed and treated in 
accordance  with  protocols  approved  by  the  Institutional  Animal  Care  and  Use 
Committees at Dana-Farber Cancer Institute and Harvard Medical School. 
 
FACS Analysis 
 
Cells were isolated and stained with anti-CD4, anti-CD8, anti-TCR, anti-CD5 and anti-
CD19 antibodies (BD Biosciences) according to the manufacture’s instructions. Briefly, 
cells were washed with PBS, blocked with 3% BSA and then stained with antibodies for 
one hour. Cells were then washed again and analyzed for surface marker staining using 
BD FACSAria IIu followed by Flowjo analysis.  
 
Histology, Wright-giemsa Staining and White Blood Cell Count 
 
For histology analysis, primary tissues were isolated, fixed with 10% buffered formalin, 
embedded in paraffin, sectioned, and stained with hematoxylin and eosin by the Dana   34 
Farber/Harvard Cancer Center Rodent Histopathology Core. For Wright-giemsa staining, 
cytospin  slides  (Thermo  Scientific)  with  primary  mouse  bone  marrow  cells  and 
peripheral blood smear slides were stained according to routine method (Lillie, 1944)  
using  Wright-giemsa  stain  (Electron  Microscopy  Sciences).  Mouse  peripheral  white 
blood cell counts were measured using HEMAVET Multispecies Hematology Analyzer 
(Drew Scientific). 
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CHAPTER THREE 
 
Translational Regulation of c-MYC in PTEN-deficient Leukemia 
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eIF4A is Essential for the Translation of c-MYC in PTEN-Deficient Leukemia 
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Abstract 
 
Highly elevated c-MYC oncoprotein abundance is found in most cases of T-cell acute 
lymphoblastic leukemia (T-ALL) and plays a key pathogenic role in this disease. Notably 
the co-occurrence of c-MYC overexpression and PTEN-deficiency is common in T-cell 
acute lymphoblastic leukemia (T-ALL). However, the mechanistic link between the two 
events resulting in this correlation has remained unclear and unexploited therapeutically. 
Using  a  genetically  engineered  murine  model  of  T-ALL  initiated  by  Pten-loss  and   37 
featuring spontaneous overexpression of c-MYC as well as a panel of PTEN-deficient 
MYC-high human T-ALL cell lines, we found that the abundance of c-MYC in these 
cells is critically dependent on hyper-activation of PI3K-mTOR-S6K1 signaling. While 
multiple mechanisms have been proposed to allow PI3K signaling to regulate c-MYC 
expression,  we  found  that  the  details  of  MYC  regulation  in  T-ALL  are  unique,  not 
occurring  via  the  regulation  of  MYC  stability  by  phosphorylation  or  the  common 
translational  initiation  machinery  via  eIF4E.  We  demonstrate  that  the  PI3K  signaling 
pathway  robustly  regulates  translation  of  MYC  via  eIF4A,  a  eukaryotic  translation 
initiation factor with intrinsic RNA helicase activity. Notably, eIF4A inhibition, either by 
RNA  interference  or  via  the  pharmacological  inhibitor  hippuristanol,  efficiently 
suppresses MYC translation and tumor cell proliferation via a mechanism specifically 
dependent  on  the  5’UTR  of  c-MYC.  Our  study  establishes  a  novel  eIF4A-dependent 
mechanism of MYC translation essential in TALL, and identifies eIF4A as a promising 
therapeutic target in c-MYC-dependent hematological malignancies. 
 
Results 
 
To establish a T-ALL tumor model driven by Pten loss, we crossed floxed Pten mice 
(Lesche et al., 2002) with transgenic mice in which Cre expression is driven by the 
proximal  Lck  promoter  (LckCre)  to  effect  genetic  ablation  of  Pten  specifically  in  T 
lymphocytes  (Hennet  et  al.,  1995).  Consistent  with  previous  studies  (Hagenbeek  and 
Spits, 2008), most LckCre
+/Pten
f/f mice developed T cell malignancies (latency, 120 days; 
penetration, 93%) (Figure 3.1A). These mice displayed significant size increases in the   38 
spleen,  liver,  thymus,  and  lymph  nodes  (Figure  3.1B)  largely  due  to  invasion  of 
lymphoblasts (Figure 3.1C). White blood cell counts were also highly elevated in the 
peripheral  blood  of  moribund  LckCre
+/Pten
f/f  mice  (Figure  3.1D),  indicating  the 
development of leukemia. Similar to previously reported VecCre
+/Pten
f/f, Mx1Cre
+/Pten
f/f 
and CD4Cre
+/Pten
f/f mice (Guo et al., 2008; Liu et al., 2010; Zhang et al., 2011), c-Myc 
protein  levels  in  the  thymocytes  of  moribund  LckCre
+/Pten
f/f  mice
  were  dramatically 
elevated (Fig 3.2A). 
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Figure 3.1 LckCre+/Pten
f/f mice developed T-ALL. 
 
(A) Kaplan-Meier survival curve for LckCre
+/Pten
f/f mice (red) (n=49, median survival 
120d), and LckCre
-/Pten
f/f control
 mice (black) (n=30).  
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Figure 3.1 (Continued) 
 
(B) Tissue weights of thymus, spleen, liver and lymph nodes of LckCre
+/Pten
f/f moribund 
mice (red) is significantly higher than that of age matched LckCre
-/Pten
f/f control
 mice 
(black).  
 
(C) Representative H&E-stained primary thymus, lymph nodes, and spleen sections and 
representative  Wright-giemsa  stained  primary  bone  marrow  cytospin  sections  and 
pheripheral blood smear sections from LckCre
+/Pten
f/f moribund mice and age matched 
LckCre
-/Pten
f/f control
 mice.  
 
(D) White blood cell counts of peripheral blood from LckCre
+/Pten
f/f moribund mice 
(red) is significantly higher than that of age matched LckCre
-/Pten
f/f control
 mice (black).  
 
 
Contributions:  Thanh  Von  assisted  with  mice  handling  in  this  figure.  Dr.  Roderick 
Bronson  and  the  Dana-Farber/Harvard  Cancer  Center  Rodent  Histopathology  Core 
conducted  histopathological  analyses  for  this  figure.  I  performed  the  rest  of  the 
experiments for this figure. 
 
   41 
 
 
Figure  3.2  Pten-Null  Driven  T-ALL  with  Over-expressed  c-Myc  is  Sensitive  to 
PI3K/AKT Inhibition 
 
(A) The abundance of c-Myc protein in the thymocytes of LckCre
+/Pten
f/f moribund mice 
is significantly higher than that of age matched LckCre
-/Pten
f/f healthy mice.  
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Figure 3.2 (Continued) 
 
(B-C) PI3K or Akt inhibition by BKM120 or MK2206 treatment as indicated reduced 
both the growth and p-Akt in LckCre
+/Pten
f/f primary tumor cells. For growth inhibition, 
indicated  drugs  were  applied  at  indicated  concentrations  for  indicated  hours  before 
measurement; for Western blotting, cells were treated with indicated drugs for one hour. 
DMSO was used as negative control.   
 
Contributions: I performed all the experiments for this figure. 
 
Our  previous  work  in  breast  cancer  models  demonstrated  that  c-Myc  overexpression 
causes resistance to PI3K inhibition (Ilic et al., 2011; Liu et al., 2011). To test whether 
leukemic cells with overexpressed c-Myc from LckCre
+/Pten
f/f mice
 are also resistant to 
PI3K inhibition, we treated primary tumor cells with BKM120 (Elfiky et al., 2011), a 
pan-PI3K inhibitor currently under clinical evaluation. To our surprise, these primary T-
ALL cells with robust c-Myc overexpression were highly sensitive to PI3K inhibition 
(Fig 3.2B). Similar results were observed in these cells when treated with MK2206, an 
AKT inhibitor currently in clinical trials (Chandarlapaty et al., 2011) (Fig 3.2C). These 
data indicate that, despite its markedly overexpressed c-Myc, T-ALL driven by Pten-loss 
in this murine model is still dependent on the PI3K-Akt pathway.  
 
To determine whether c-Myc levels in Pten-null driven T-ALL are altered in response to 
PI3K  or  Akt  inhibition,  we  treated  primary  tumor  cells  isolated  from  moribund   43 
LckCre
+/Pten
f/f mice with either BKM120 or MK2206, and then measured the protein 
abundance of c-Myc. Notably, both PI3K and AKT inhibitors dramatically decreased the 
abundance of c-Myc protein in these cells in a dose-dependent manner (Fig 3.3A-3.3B). 
Furthermore, we found that restoring the expression of Pten in these primary Pten-null T-
ALL cells greatly reduced the abundance of c-Myc protein as well as the phosphorylation 
of  both  Akt  and  S6RP  (Fig  3.3C).  These  data  indicate  that  the  PI3K/Akt  signaling 
pathway tightly controls the abundance of c-Myc protein in this T-ALL model driven by 
Pten-loss.  
 
We  next  extended  our  finding  to  human  T  cell  lymphoma/leukemia  cell  lines.  We 
screened a panel of T cell lymphoma or T-ALL cells. Out of thirteen cell lines tested, we 
found that six cell lines demonstrated either low or undetectable expression of PTEN (Fig 
3. 3D). Notably, in all the six cell lines, AKT inhibition by MK2206 decreased c-MYC 
protein levels (Fig 3.3E). Ectopic expression of PTEN also decreased c-MYC levels in 
human  PTEN-deficient  T-ALL  cell  lines  (Fig  3.  3F).  These  results  suggest  the  link 
between PI3K/AKT pathway activation and c-MYC protein elevation observed in our 
murine model of Pten-null T-ALL is also evident in most PTEN-deficient human T-ALL 
cell lines. 
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Figure  3.3  Inhibition  of  PI3K  or  AKT  Activity  Reduces  the  Amount  of  c-MYC 
Protein in both Murine Pten-Null T-ALL and Human PTEN-Deficient T-ALL 
 
(A-B) The abundance c-Myc protein in LckCre
+/Pten
f/f primary tumor cells was reduced 
upon one hour treatment with BKM120 or MK2206 in a dose-dependent manner.  
 
(C) Ectopic expression of Pten suppressed c-Myc protein level and PI3K signaling in 
LckCre
+/Pten
f/f primary tumor cells.  
 
(D)  The  abundances  of  both  c-MYC  protein  and  PI3K  signaling  in  human  PTEN-
deficient T-ALL cells are reduced upon one hour treatment with MK2206.  
 
(E) The abundances of both c-MYC protein and PI3K signaling in human PTENdeficient 
T-ALL cells are reduced upon one hour treatment with MK2206. 
 
(F) Ectopic expression of PTEN suppressed c-MYC protein level and PI3K signaling in 
PTEN deficient T-ALL cell lines HPB-ALL and PF382. 
 
Contributions: I performed all the experiments in this figure. 
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Figure 3.3 (Continued) 
 
 
Contributions: I performed all the experiments in this figure. 
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We next sought to understand the nature of the regulation of c-Myc by the PI3K-Akt 
pathway activation. We first determined that gene expression levels of Myc are increased 
in  our  LckCre
+/Pten
f/f  primary  tumor  cells  (Fig  3.4A),  consistent  with  previously 
described Pten-null T-ALL models (Guo et al., 2008; Liu et al., 2010; Zhang et al., 2011) 
Interestingly, while PI3K/Akt inhibition caused a dramatic decrease of c-Myc protein 
abundance (Fig 3.3), the level of Myc mRNA in these cancer cells was not altered upon 
treatment  with  the  AKT  inhibitor,  MK2206  (Fig  3.4B),  suggesting  that  the  gene 
expression of Myc is not affected by PI3K/Akt activity.  
 
It has been reported that, GSK3β, a downstream effector of AKT, can regulate c-MYC 
protein stability through phosphorylation of c-MYC at the threonine-58 residue (T58) and 
subsequent proteasome-mediated degradation (Sears et al., 2000). To test whether this 
mechanism is also functioning in our T-ALL model, we treated the primary T-ALL cells 
with  the  translation  elongation  inhibitor  cycloheximide  (CHX)  either  alone  or  in 
combination with MK2206. Application of CHX suppresses biosynthesis and as a result, 
c-Myc protein levels quickly decreased due to the protein’s short half-life. Addition of 
MK2206, however, failed to either expedite or postpone the degradation of c-Myc (Fig 
3.4C). These results indicate that PI3K/Akt signaling has little effect on the stability of c-
Myc protein in these T-ALL cells. 
 
We next tested whether the PI3K pathway regulates de novo synthesis of the c-Myc 
protein. LckCre
+/Pten
f/f primary tumor cells were pre-treated with CHX to deplete c-Myc 
protein, and CHX was subsequently washed away, quickly followed by the addition of   47 
MG132,  a  proteasome  inhibitor,  to  preserve  newly  synthesized  c-Myc.  As  expected, 
newly synthesized c-Myc was stabilized and accumulated in MG132 treated cells, but not 
in cells treated with MG132 plus CHX (Fig 3.4D). Strikingly, little c-Myc protein was 
detected  in  cells  treated  with  MG132  plus  MK2206  (Fig  3.4D),  suggesting  that  Akt 
inhibition profoundly blocked de novo synthesis of c-Myc.  
 
 
 
Figure 3.4 The PI3K-mTORC1-S6K1 Signaling Regulates c-Myc de novo Synthesis 
in Pten-Deficient T-ALL  
 
(A)  The  expression  levels  of  c-Myc  mRNA  in  the  thymocytes  of  LckCre
+/Pten
f/f 
moribund mice are significantly higher than that of age matched LckCre
-/Pten
f/f healthy 
mice.   
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Figure 3.4 (Continued) 
 
(B)  The  expression  levels  of  c-Myc  mRNA  in  primary  T-ALL  cells  derived  from 
LckCre
+/Pten
f/f mice remain unchanged upon 1µM MK2206 treatment at the indicated 
time points. c-Myc mRNA levels were measured by quantitative PCR. GAPDH was used 
as control.  
 
(C) The c-Myc protein stability in primary T-ALL cells derived from LckCre
+/Pten
f/f 
mice remained unchanged upon MK2206 treatment for the indicated time points.  Cells 
treated with 25µg/ml cycloheximide (CHX) with or without 1µM MK2206 are indicated.  
 
(D)  AKT  inhibition  blocked  the  de  novo  synthesis  of  c-Myc  protein.  LckCre
+/Pten
f/f 
primary tumor cells (lane 1) were pre-treated with 25µg/ml CHX for two hours to deplete 
c-Myc  protein  (lane  2)  and  cells  were  washed  three  times  with  PBS  to  allow  new 
biosynthesis. MG132 was then added at 10µM either alone (lane 3) or with 25µg/ml 
CHX (lane 4) or with 1µM MK2206 (lane 5) for one hour.  
 
We next set out to examine the mechanism by which the PI3K/Akt pathway regulates c-
Myc translation in LckCre
+/Pten
f/f primary tumor cells.  We first tested the effect of the 
inhibition  of  mTORC1,  an  essential  downstream  effector  of  PI3K/Akt  known  to  be 
critical  for  translational  control,  on  the  c-Myc  protein  abundance  in  these  cells.  We 
treated the LckCre
+/Pten
f/f primary tumor cells with an mTORC1 inhibitor RAD001 or 
the PI3K/mTORC1 dual inhibitor BEZ235 (Maira et al., 2008; Schuler et al., 1997) and   49 
found that both inhibitors indeed dramatically suppressed c-Myc protein levels and the 
downstream  signaling  of  their  targets  (Fig  3.5A-3.5B).  The  growth  of  these  primary 
tumor cells was also markedly reduced in a dose-dependent manner (Fig 3.5A-3.5B). 
Similar  to  MK2206  described  above,  neither  BEZ235  nor  RAD001  affected  Myc 
transcription or degradation in primary cells (Fig 3.5C-3.5D).  To determine whether the 
phenotype we observed in vitro can be replicated in vivo, we measured the ability of the 
PI3K/mTORC1 dual inhibitor BEZ235 (Maira et al., 2008) to suppress tumor growth and 
c-Myc protein levels in vivo (Fig 3.5E-3.5G). 
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Figure 3.5 The mTORC1-S6K Signaling Regulates c-Myc de novo Synthesis in Pten- 
Deficient T-ALL 
 
(A-B)  PI3K  or  mTORC1  inhibition  by  RAD001  or  BEZ235  treatment  as  indicated 
reduced both the growth and c-Myc protein abundance in LckCre+/Ptenf/f primary tumor 
cells. For growth inhibition, indicated drugs were applied at indicated concentrations for 
indicated  hours  before  measurement;  for  Western  blotting,  cells  were  treated  with 
indicated drugs for two hours. DMSO was used as negative control. 
 
(C)  The  expression  levels  of  c-Myc  mRNA  in  primary  T-ALL  cells  derived  from 
LckCre+/Ptenf/f  mice  remain  unchanged  upon  100nM  BEZ235  or  100nM  RAD001 
treatment  at  the  indicated  time  points.  c-Myc  mRNA  levels  were  measured  by 
quantitative PCR. GAPDH was used as control. 
 
(D) The c-Myc protein stability in primary T-ALL cells derived from LckCre+/Ptenf/f 
mice remained unchanged upon RAD001 or BEZ235 treatment for the indicated time 
points. Cells treated with 25µg/ml cycloheximide (CHX) alone or with 100nM RAD001, 
or 100nM BEZ235 are indicated. 
 
(E)  Recipient  mice  transplanted  with  two  million  LckCre+/Ptenf/f  moribund  mice 
thymocytes showed prolonged survival curve with daily BEZ235 treatment (35mg/kg) 
compared to control treatment. Arrow indicates the starting date of treatment (day 14) 
post transplantation.   51 
Figure 3.5 (Continued) 
 
(F-G)  Recipient  mice  transplanted  with  two  million  LckCre+/Ptenf/f  moribund  mice 
thymocytes showed suppressed PI3K signaling as measured by p-Akt (S473), p-S6RP 
(S235/236)  IHC  staining  (F),  deceased  proliferation  rate  as  measured  by  Ki67  IHC 
staining (F) and decreased c-Myc protein levels as detected by Western blotting (G) after 
three days of BEZ235 daily treatment (35mg/kg), starting at 14 days post transplantation. 
PEG300 was used as control treatment for in vivo inhibitor administration. 
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Figure 3.5 (Continued) 
 
 
 
Contributions: Thanh Von, Dr. Lukas Baitsch and Dr. Haluk Yuzugullu assisted with 
mice  handling  and  FACS  analysis  for  in  this  figure.  I  performed  the  rest  of  the 
experiments for this figure.   53 
While mTORC1 has been previously implicated in regulating c-MYC, the mechanism 
remains  unclear.  The  traditional  model  is  that  mTORC1  stimulates  translation  by 
phosphorylating  the  eIF4E-binding  protein  (4EBP1),  which  blocks  the  inhibitory 
interaction of 4EBP1 with eIF4E, rending eIF4E available for binding to eIF4G and thus 
recognition  of  the  5’-cap.  Given  the  well-established  significance  of  assembling  the 
eIF4E/eIF4G complex in translation initiation, we first tested whether a small molecule 
inhibitor termed 4EGI-1 that blocks the interaction of eIF4E with eIF4G could reduce c-
Myc protein abundance as we have recently shown that 4EGI-1 significantly reduced the 
c-MYC protein translation in human melanoma and breast cancer cells. To our surprise, 
4EGI-1 treatment greatly increased c-Myc protein abundance in these T-ALL cells (Fig. 
3.6A). Interestingly, 4EGI-1 also increased pS6RP levels (Fig. 3.6A).  To investigate 
whether S6K1 plays a role in regulating c-Myc protein in our Pten-null T-ALL model, 
we  utilized  a  small  molecule  inhibitor  of  S6K1,  PF470861.  Notably  S6K1  inhibition 
effectively  decreased  c-Myc  protein  levels  and  inhibited  tumor  cell  proliferation  in  a 
dose-dependent manner (Fig 3.6B). Similar to the inhibition of its upstream activators, 
S6K1 inhibition did not affect gene transcription or protein stability of c-Myc (Fig 3.6C-
3.6D).    Consistent  with  the  treatment  of  MK2206,  application  of  either  RAD001  or 
BEZ235,  or  PF470861  markedly  prevented  c-Myc  protein  de  novo  synthesis  in 
LckCre
+/Pten
f/f  primary  tumor  cells  (Fig  3.6E).  Together,  our  results  indicate  the 
mTORC1-S6K1 axis downstream of PI3K/Akt plays a critical role in the regulation of c-
Myc de novo synthesis.  
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Figure 3.6 The S6K1 Downstream of PI3K/mTORC1 Regulates c-Myc de novo 
Synthesis 
 
(A) Inhibition of eIF4E and eIF4G interaction by 4EGI-1 increased pS6RP and c-Myc 
protein level. Cells were treated with 4EGI-1 at indicated concentrations for four hours. 
DMSO was used as negative control. 
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Figure 3.6 (Continued) 
 
(B) S6K1 inhibition by PF4708671 treatment as indicated reduced both the growth and c- 
Myc protein abundance in LckCre+/Ptenf/f primary tumor cells. For growth inhibition, 
PF4708671  was  applied  at  indicated  concentrations  for  indicated  hours  before 
measurement; for Western blotting, cells were treated with indicated drugs for two hours. 
DMSO was used as negative control. 
 
(C) PI3K, mTORC1 or S6K1 inhibition by RAD001, BEZ230 or PF4708671 treatment as 
indicated blocked the de novo synthesis of c-Myc protein. LckCre+/Ptenf/f primary tumor 
cells (lane 1) were pre-treated with 25µg/ml CHX for two hours to deplete c-Myc protein 
(lane 2) and cells were washed three times with PBS to allow new biosynthesis. MG132 
was then added at 10µM either alone (lane 3), or with 25µg/ml CHX (lane 4), or with 100 
nM RAD001 (lane 5), or with 100nM BEZ235 (lane 6), or with 10µM PF4708671 (lane 
7) for two hours. 
 
(D)  The  expression  levels  of  c-Myc  mRNA  in  primary  T-ALL  cells  derived  from 
LckCre+/Ptenf/f mice remain unchanged upon 10µM PF4708671 treatment at the indicated 
time points. c-Myc mRNA levels were measured by quantitative PCR. GAPDH was used 
as control. 
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Figure 3.6 (Continued) 
 
(E) The c-Myc protein stability in primary T-ALL cells derived from LckCre+/Ptenf/f 
mice remained unchanged upon treatment for the indicated time points. Cells treated 
with 25µg/ml cycloheximide (CHX) with or without 10µM PF4708671 are indicated. 
 
Contributions: I performed all the experiments for this figure. 
 
We have shown that that c-MYC protein levels were inhibited by application of the AKT 
inhibitor MK2206 in a panel of human PTEN-deficient T-ALL cell lines (Fig 3.3).  To 
determine  whether  mTORC1  can  also  regulate  c-MYC  in  human  PTEN-deficient  T-
ALLs,  we  treated  the  previously  described  eight  cell  lines  (Fig  3.3)  with  RAD001. 
Similar to the inhibition of AKT, mTORC1 inhibition in all these cell lines decreased c-
MYC protein abundance (Fig 3.7A). We then focused our subsequent studies in two 
PTEN-deficient, c-MYC high T-ALL cell lines, HPB-ALL and PF382. Similar to the 
inhibition of mTORC1, inhibition of S6K1 also greatly suppressed c-MYC protein levels 
in HPB-ALL and PF382 (Fig 3.7B-3.7C). Consistent with our findings in the primary 
cells, the application of MK2206, or RAD001, or PF470861 had little effect on neither 
gene expression of MYC (Fig 3.7D-3.7E) or c-MYC protein stability (Fig 3.7F-3.7G) in 
both cell lines. Impressively, all these inhibitors targeting the AKT-mTORC1-S6K1 axis 
showed strong inhibition of the de novo sysnthesis of c-MYC protein (Fig 3.7H-3.7I), 
Notably, inhibition of the eIF4E/eIF4G interaction by 4EGI-1 in these human PTEN-
deficient T-ALL cells also led to the same perplexing results seen in mouse primary Pten-  57 
null T-ALL cells: increased levels of c-MYC protein and pS6RP (Fig. 3J), suggesting 
that  the  translation  of  c-MYC  in  these  leukemic  cells  is  uniquely  regulated  by  the 
PI3K/mTOR/S6K pathway activation. 
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Figure 3.7 The mTORC1-S6K1 Axis Regulates the de novo Synthesis of c-MYC 
Protein in Human PTEN-Deficient T-ALL Cell Lines 
 
(A) The abundances of both c-MYC protein and PI3K signaling in human PTENdeficient 
T-ALL cells are reduced upon one hour treatment with MK2206 or RAD001. 
 
(B-C) The abundances of c-MYC protein were reduced upon RAD001 or PF4708671 
treatment in HPB-ALL and PF382 cells. DMSO treatment was used as negative control. 
 
(D-E) Inhibition of AKT/mTORC1/S6K1 did not change the level of MYC transcription. 
HPB-ALL  cells  (D)  or  PF382  cells  (E)  were  treated  with  MK2206,  RAD001  or 
PF4708671 for one to four hours as indicated. c-MYC mRNA levels were measured by 
quantitative PCR. GAPDH was used as control. 
 
(F-G) Inhibition of AKT/mTOR/S6K1 did not affect c-MYC protein stability. HPB-ALL 
cells (F) or PF382 cells (G) were treated with 25µg/ml cycloheximide (CHX) with or 
without MK2206, RAD001 or PF4708671 for the indicated time points. Cell lysates were 
subjected to Western blotting, followed by quantification. 
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Figure 3.7 (Continued) 
 
(H-I) The de novo synthesis of c-MYC protein was inhibited by AKT/mTORC1/S6K1 
inhibition. HPB-ALL (H) or PF382 (I) cells (lanes 1) were pre-treated with 25µg/ml 
CHX for two hours to deplete c-Myc protein (lanes 2) and cells were washed three times 
with PBS to allow new biosynthesis. MG132 was then added either alone (lanes 3) or 
with  CHX  (lanes  4)  or  with  MK2206  (lanes  5),  or  with  RAD001  (lanes  6),  or  with 
PF4708671 (lanes 7) for two hours. 
 
(J) Inhibition of eIF4E and eIF4G interaction by 4EGI-1 increased pS6RP and c-Myc 
protein level. HPB-ALL cells were treated with 4EGI-1 at indicated concentrations for 
four hours. DMSO was used as negative control. 
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Figure 3.7 (Continued) 
 
   61 
Figure 3.7 (Continued) 
 
 
 
We  next  investigated  how  mTORC1/S6K1  regulates  c-MYC  protein  synthesis.  The 
mRNA of MYC contains a highly structured 5' untranslated region (5'UTR) (Stoneley et 
al., 1998) that has been implicated in regulating its translation (Galmozzi et al., 2004). To 
test whether the MYC 5’UTR is critical for the translational control of c-MYC by the 
PI3K/mTORC1/S6K1  pathway,  we  used  a  luciferase  construct  in  which  the  SV40 
promoter drives firefly luciferase expression either with or without a MYC 5’UTR (Fig 
3.8A). A renilla luciferase construct was used as internal control. We tested the response 
of luciferase report activity to inhibitors targeting the PI3K pathway. Notably, treatment 
with either BEZ235 or PF470861 significantly reduced the luciferase activity expressed 
from the construct containing the MYC 5’UTR, but not the one lacking a MYC 5’UTR 
(Fig 3.8A). These data suggest that the PI3K/mTORC1/S6K1 pathway regulates MYC 
translation via its structured 5’UTR. 
 
To further validate whether MYC 5’UTR is important for its translation regulated by the 
PI3K/mTORC1/S6K1 signaling axis in PTEN-deficient T-ALL, we utilized a retroviral 
expression vector to introduce a stabilized mutant allele of MYC, MYC T58A, with or   62 
without the MYC 5’UTR, into HPB-ALL cells, resulting in a pair of isogenic lines: HPB-
ALL  MYC  T58A  -5’UTR  and  HPB-ALL  MYC  T58A  +5’UTR.  Strikingly,  while  the 
abundance of c-MYC protein in HPB-ALL MYC T58A -5’UTR cells was little changed 
in response to either BEZ235 or PF4708671, it was markedly reduced in cells expressing 
HPB-ALL MYC T58A +5’UTR in response to inhibitors treatment despite the presence 
of the stabilizing mutant c-MYC T58A (Fig 3.8B-3.8C). Notably, the abundance of c-
MYC protein in the parental cells expressing vector control also dramatically reduced by 
the inhibitor treatments (Fig 3.8B-3.8C), suggesting that endogenous MYC mRNAs in 
these  T-ALL  cells  carrying  5’UTR  are  subjected  to  the  regulation  by  the 
PI3K/mTORC1/S6K activity. We have further confirmed that the 5’UTR is present in the 
Myc mRNA transcripts in the Pten-null T-ALL derived from LckCre
+/Pten
f/f mice as well 
as in a panel of human PTEN-deficient c-MYC high T-ALL lines that we have tested.  
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Figure 3.8 The PI3K/mTOR/S6K1 Signaling Regulates c-MYC 5’UTR 
 
 
(A) The activity of firefly luciferase reporter in the construct carrying a MYC 5’UTR is 
sensitive to the inhibition of PI3K/mTORC1 or S6K1. Normalized units of luciferase 
activities in the cell lysates from co-transfection of the pGL3 with or without the 5’UTR 
of human MYC and the pRL renilla luciferase reporter as internal control are shown. 
Luciferase activities were measured in cells treated with BEZ235 or PF4708671 for four 
hours two days post transfection. ***P< 0.0005 (Student’s t test). 
 
(B-C)  The  differential  responses  of  c-MYC  protein  abundance  in  HPB-ALL  cells 
expressing vector control, MYC T58A -5’UTR or MYC T58A +5’UTR upon BEZ235 or 
PF4708671 treatment as indicated. 
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Since the ectopically expressed  MYC T58A constructs in this experiment had no tag 
attached, their protein bands were superimposed with endogenous c-MYC in the western 
blotting analysis (Fig 3.5B-3.5C). We then expressed a Flag-tagged MYC T58A -5’UTR 
in HPB-ALL and a number of additional T-ALL cell lines to display a Flag-tagged c-
MYC T58A that is distinct from the endogenous c-MYC (Fig 3.9A-3.9E). Our results 
clearly show that, while the abundance of the Flag-tagged c-MYC T58A protein in cells 
remained unchanged in response to PI3K, AKT or mTORC1 inhibitors, the amount of 
endogenous c-MYC reduced dramatically upon treatment with these drugs (Fig 3.9A-
3.9E).  Consistent  with  this  finding,  HPB-ALL  MYC  T58A  -5’UTR  cells  have 
significantly reduced sensitivity to growth inhibition upon treatment with PI3K/mTORC1 
or S6K1 inhibitors as compared to parental cells or the isogenic HPB-ALL MYC T58A 
+5’UTR cells (Fig 3.9F-3.9J). The fact that growth inhibition of PI3K/mTORC1 and 
S6K1 inhibitors is not fully rescued by expressing the exogenous c-MYC suggest that in 
addition to c-MYC, other downstream targets were also regulated by PI3K/mTORC1 and 
S6K1  signaling.  Together,  these  data  demonstrate  that  the  PI3K/mTORC1/S6K1 
signaling axis governs the translation of MYC mRNAs bearing 5’UTR. 
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Figure  3.9  The  PI3K/mTOR/S6K1  Signaling  Regulates  the  5’UTR-Dependent 
Translation of c-Myc. 
 
(A-C) The response of Flag-tagged c-MYC T58A protein or endogenous c-MYC protein 
abundance  in  HPB-ALL  cells  upon  BKM120,  MK2206  or  RAD001  treatment  as 
indicated. 
 
(D-E) The response of Flag-tagged c-MYC T58A protein or endogenous c-MYC protein 
abundance in PTEN-deficient T-ALL cells Supt13 (D), and PF382 (E) upon BEZ235 
treatment as indicated. 
 
(F-G) The differential responses of the growth rate of HPB-ALL cells expressing vector, 
MYC T58A -5’UTR, or MYC T58A +5’UTR as indicated upon BEZ235 or PF4708671 
treatment. **P < 0.005 (Student’s t test). 
 
(H-J) The differential responses of the growth rate of HPB-ALL cells expressing vector, 
or MYC T58A -5’UTR as indicated upon BKM120 (H), MK2206 (I), or RAD001 (J) 
treatment. *P<0.05, **P< 0.005 (Student’s t test). 
 
 
 
 
   66 
Figure 3.9 (Continued) 
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Previous studies have shown that S6K1 can phosphorylate the translation initiation factor 
eIF4B (Raught et al., 2004), which has been implicated in facilitating the helicase activity 
of the dead-box RNA helicase eIF4A (Andreou and Klostermeier, 2013; Rogers et al., 
1999). eIF4A has been shown to be important in the unwinding of structured 5’UTRs for 
translation initiation (Lawson et al., 1986; Parsyan et al., 2011). To test whether eIF4B 
and elF4A are involved in the translational regulation of MYC in our leukemic cells, we 
introduced multiple shRNAs against eIF4B or eIF4A into HPB-ALL cells. Notably, the 
knock-down  efficiency  of  either  eIF4B  or  eIF4A  closely  correlated  with  both  the 
reduction of c-MYC protein levels in these cells, as well as the reduction of tumor cell 
proliferation (Fig 3.10A-3.10D), suggesting that both eIF4B and elF4A are important in 
regulating  the  translation  of  c-MYC.  Taken  together,  our  results  demonstrate  that  in 
PTEN-deficient  and  c-MYC  overespressing  T-ALL  cells,  the  hyper-activated 
PI3K/mTORC1/S6K1 signaling axis is critical for the translation of elevated number of 
MYC transcripts bearing 5’UTR via an eIF4B/eIF4A mediated translational mechanism. 
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Figure 3.10 Translation Initiation Factor eIF4A/eIF4B Regulates c-MYC and 
Tumor Cell Proliferation 
 
(A-B) The change of the abundance of c-MYC protein and growth rate of HPB-ALL cells 
in response to shRNA-mediated knockdown of eIF4B. Cells expressing scramble control 
(Scr), or five independent shRNA constructs against eIF4B as indicated. *P< 0.05, 
***P<0.0005 (n=3, Student’s t test). 
 
(C-D) The change of the abundance of c-MYC protein and growth rate of HPB-ALL 
cells in response to shRNA-mediated knockdown of eIF4A. Cells expressing scramble 
control (Scr), or five independent shRNA constructs against eIF4A, as indicated. *P< 
0.05, ***P<0.0005 (n=3, Student’s t test). 
 
Contributions: I performed all the experiments for the figure. 
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We next examined whether the helicase activity of eIF4A is important for the translation 
control of MYC using hippuristanol, a selective enzymatic inhibitor of eIF4A (Bordeleau 
et  al.,  2006).  We  first  tested  primary  Pten-null  T-ALL  cells  isolated  from  our 
LckCre
+/Pten
f/f mice and found that hippuristanol effectively reduced the c-Myc protein 
levels and the growth of these primary tumor cells in a dose dependent manner (Fig 
3.11A-3.11B). We further confirmed that hippuristanol did not affect Myc transcription or 
degradation (Fig 3.11C-3.11D), but instead strongly blocked Myc translation (Fig 3.11E).  
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Figure  3.11  Hippuristanol,  a  Small  Molecule  Inhibitor  of  elF4A,  Blocks  the 
Translation of c-MYC in T-ALL 
 
(A)  The  response  of  the  growth  rate  of  primary  LckCre+/Ptenf/f  T-ALL  cells  upon 
hippuristanol treatment. Hippuristanol was applied to cells at the indicated concentrations 
for indicated hours before measurement. 
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Figure 3.11 (Continued) 
 
 
(B) The response of the abundance of c-Myc in primary LckCre+/Ptenf/f T-ALL cells 
upon  hippuristanol  treatment.  Hippuristanol  was  applied  to  cells  at  the  indicated 
concentrations for two hours. DMSO treatment was used as negative control. 
 
(C) The de novo synthesis of c-Myc protein in primary LckCre+/Ptenf/f T-ALL cells is 
inhibited by hippuristanol treatment. Cells were pre-treated with 25µg/ml CHX for two 
hours to deplete c-Myc protein (lanes 1-2), and subsequently washed three times with 
PBS to allow new biosynthesis. MG132 was then added at 10µM either alone (lanes 3) or 
with 25µg/ml CHX (lanes 4) or with 1µM hippuristanol (lanes 5) for two hours. 
 
(D) Inhibition of eIF4A helicase activity did not change the level of MYC transcription. 
Primary LckCre+/Ptenf/f T-ALL cells were treated with hippuristanol for one to four hours 
as indicated. c-MYC mRNA levels were measured by quantitative PCR. GAPDH was 
used as control. 
 
(E) Inhibition of eIF4A helicase activity did not affect c-MYC protein stability. Primary 
LckCre+/Ptenf/f T-ALL cells were treated with 25µg/ml cycloheximide (CHX) with or 
without  hippuristanol  for  the  indicated  time  points.  Cell  lysates  were  subjected  to 
Western blotting, followed by quantification. 
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Again we extended the experiment from our murine primary T-ALL model to human 
cancer  cell  lines.  Consistent  with  the  findings  in  primary  LckCre
+/Pten
f/f  T-ALL, 
hippuristanol greatly reduced c-MYC protein levels in c-MYC dependent human T-ALL 
cell  lines  in  a  dose-dependent  manner  (Fig  3.12A-3.12B).  We  also  confirmed  that 
hippuristanol  prevented c -MYC  translation  without  affecting  its  transcription  or 
degradation (Fig 3.12C-3.12E). 
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Figure  3.12  Hippuristanol  Blocks  the  Translation  of  c-MYC  in  human 
PTENdeficient T-ALL cell lines. 
 
(A-B) The response of the abundance of c-Myc in HPB-ALL (A) and PF382 (B) cells 
upon  hippuristanol  treatment.  Hippuristanol  was  applied  to  cells  at  the  indicated 
concentrations for two hours. DMSO treatment was used as negative control. 
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Figure 3.12 (Continued) 
 
(C)  The  de  novo  synthesis  of  c-Myc  protein  in  HPB-ALL  cells  is  inhibited  by 
hippuristanol  treatment.  Cells  were  pre-treated  with  25µg/ml  CHX  for  two  hours  to 
deplete c-Myc protein (lanes 1-2), and subsequently washed three times with PBS to 
allow new biosynthesis. MG132 was then added at 10µM either alone (lanes 3) or with 
25µg/ml CHX (lanes 4) or with 1µM hippuristanol (lanes 5) for two hours. 
 
(D) Inhibition of eIF4A helicase activity did not change the level of MYC transcription. 
HPB-ALL cells were treated with hippuristanol for one to four hours as indicated. c- 
MYC mRNA levels were measured by quantitative PCR. GAPDH was used as control. 
 
(E) Inhibition of eIF4A helicase activity did not affect c-MYC protein stability. HPBALL 
cells were treated with 25µg/ml cycloheximide (CHX) with or without hippuristanol for 
the indicated time points. Cell lysates were subjected to Western blotting, followed by 
quantification. 
 
To determine whether hippuristanol selectively targets the MYC 5’UTR, we treated the 
isogenic cell lines HPB-ALL MYC T58A -5’UTR and HPB-ALL MYC T58A +5’UTR 
with the inhibitor. Notably, while the c-MYC protein in HPB-ALL MYC T58A -5’UTR 
cells was little changed in response to hippuristanol treatment, c-MYC protein levels in 
both parental and HPB-ALL MYC T58A +5’UTR cells were markedly reduced in the 
presence  of  hippuristanol  (Fig  3.13A).  Consistent  with  this  finding,  HPB-ALL  MYC   75 
T58A -5’UTR cells were more resistant to growth inhibition induced by hippuristanol as 
compared to parental cells or the isogenic HPB-ALL MYC T58A +5’UTR (Fig 3.13B). 
These data suggest that the unwinding the structured 5’UTR of MYC mediated by the 
helicase activity of eIF4A is important for the translation of MYC. The fact that growth 
inhibition  of  hippuristanol  is  not  fully  rescued  by  expressing  the  exogenous  c-MYC 
suggests  that  in  addition  to  c-MYC,  other  targets  were  also  regulated  by  eIF4A. 
Furthermore, we found that hippuristanol effectively inhibited the proliferation of a panel 
of human PTEN-deficient, c-MYC high T-ALL cell lines at relatively low concentrations 
(Fig 3.13C). These data collectively indicate the therapeutic potential of targeting eIF4A 
for T-ALLs dependent on pathologically activated c-MYC. 
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Figure 3.13 Hippuristanol Blocks the 5’UTR-Dependent Translation of c-MYC in T-
ALL 
 
(A)  The  differential  response  of  the  c-MYC  protein  abundance  in  HPB-ALL  cells 
expressing  vector  control,  MYC  T58A  -5’UTR,  or  MYC  T58A  +5’UTR  upon 
hippuristanol treatment. Cells were treated with 1µM hippuristanol for two hours before 
being subjected to Western blotting analysis. 
 
(B) The differential response of the growth rate of HPB-ALL cells expressing vector 
control, MYC T58A -5’UTR, or MYC T58A +5’UTR upon hippuristanol treatment. Cells 
were treated with 1µM hippuristanol for seventy-two hours at indicated concentrations. 
DMSO treatment was used as negative control. *P<0.05, **P<0.005 (n=3, Student’s t 
test). 
 
(C) Hippuristanol effectively inhibits cell proliferation of a panel of PTEN-deficient, c-
MYC-high T-ALL cell lines with IC50 at nm range. Cells were seeded into 96-well 
plates and hippuristanol was applied at concentration gradients. Seventy-two hours after 
the drug treatment, cell proliferation was measured by MTS assay with IC50s calculated 
using Prism 6. 
 
Contributions: I performed all the experiments for this figure. 
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Figure 3.13 (Continued) 
 
 
 
 
 
To further investigate whether our finding in PTEN-deficient T-ALLs can be extended to 
other  PTEN-deficient  hematological  malignancies,  we  screens  another  twenty-five 
hematological cancer cell lines and found that six of them showed low or undetectable 
PTEN levels (Fig 3. 14A). Impressively, c-Myc protein levels were inhibited upon either 
AKT  or  mTOR  inhibitor  treatment  in  all  these  six  cell  lines  (Fig  3.  14B).  We  also 
confirmed that hippuristanol effectively inhibited c-MYC protein levels (Fig 3. 14C) and 
consequently blocked tumor cell proliferation (Fig 3. 14D) in these lines. These data   78 
collectively indicate the efficiency to target the c-MYC translation regulatory pathway 
for c-MYC dependent hematological malignancies. 
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Figure 3. 14 Hippristanol inhibited c-MYC translation in hematological cancer cell 
lines. 
 
(A) Six (red) out of twenty-five hematological cancer cell lines (HL60, Molm13, MV4- 
11,  OCI-AML2,  THP-1,  U937:  AML;  Daudi,  Namalwa:  Burkitt  Lymphoma;  K562: 
Chronic  Myeloid  Leukemia,  CML;  DOHH2,  HT,  OCI-LY19,  TMD8,  U2932, 
WSUDLCL2,  Su-DHL-4,  Su-DHL-5,  Su-DHL-6:  DLBCL;  MC116,  SKW-1:  B  cell 
lymphoma; Molp8, OPM2, NCI-H929, RPMI8226: MM; NB-4: Acute Promyelocytic 
Leukemia, APL) showed low or undetectable PTEN protein levels. 
 
(B) MK2206 or RAD001 treatment inhibited c-MYC protein level in human PTEN null 
hematological cancer cell lines. 1µM MK2206 or 10 nM RAD001 was added for one 
hour and DMSO treatment was used as negative control. 
 
(C) Dose dependent inhibition of c-MYC protein abundance in WSU-DLCL2 and 
MC116 cells after two hours treatment with hippuristanol. 
 
(D) Hippuristanol inhibits cell proliferation in a panel of PTEN null, c-Myc dependent 
hematological cancer cell lines. Cells were seeded into 96-well plates and hippuristanol 
was  applied  at  concentration  gradients.  Seventy-two  hours  after  initial  inhibitor 
application, cell proliferation was measured by MTS assay with IC50s calculated using 
Prism 6. 
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Figure 3.14 (Continued) 
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To test whether the inhibition of c-Myc translation is effective in c-Myc dependent cells 
that are insensitive to inhibition of c-Myc transcription, we tested Jurkat (T-ALL) and 
K562 (CML) cells. These lines both feature MYC amplification and are insensitive to 
JQ1 treatment (Zuber et al., 2011). To our interest, hippuristanol effectively inhibited cell 
proliferation  in  comparison  to  JQ1  in  both  cell  lines  (Fig  3.15A-3.15B).  We  further 
confirmed that JQ1 failed to inhibit c-Myc trancription in Jurkart cells (Fig 3.15C). On 
the other hand, hippuristanol effectively inhibited c-Myc translation, but not transcription 
or degradation (Fig 3.15D-3.15F). These data demonstrate the benefit to target c-Myc 
translation in hematological cancer cells insensitive to JQ1-mediated MYC transcription 
suppression. 
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Figure  3.15  Hippuristanol,  a  Small  Molecule  Inhibitor  of  elF4A,  Blocks  c-MYC 
Translation in JQ1 Insensitive Cell Lines 
 
(A-B)  The  response  of  the  growth  rate  of  K562  cells  (A)  and  Jurkat  cells  (B)  upon 
hippuristanol or JQ1 treatment. Hippuristanol or JQ1 was applied to cells at the indicated 
concentrations for seventy-two hours before measurement. 
 
(C) The expression levels of c-Myc mRNA in Jurkat cells remain unchanged upon 1µM 
JQ1  treatment  at  the  indicated  time  points  whereas  JQ1  effectively  inhibited  c-MYC 
mRNA levels in JQ1 sensitive cell line OPM2. c-Myc mRNA levels were measured by 
quantitative PCR. GAPDH was used as control.  
 
(D) The expression levels of c-Myc mRNA in Jurkat cells remain unchanged upon 1µM 
Hippuristanol treatment at the indicated time points. c-Myc mRNA levels were measured 
by quantitative PCR. GAPDH was used as control. 
 
(E) The response of the abundance of c-Myc protein in Jurkat cells upon hippuristanol 
treatment. Hippuristanol was applied at 1µM at indicated times. DMSO treatment was 
used as negative control. 
 
(F) Inhibition of eIF4A did not affect c-MYC protein stability. Jurkat cells were treated 
with 25µg/ml cycloheximide (CHX) with or without Hippuristanol for the indicated time 
points. Cell lysates were subjected to Western blotting, followed by quantification.   83 
Figure 3.15 (Continued) 
 
(G) The de novo synthesis of c-Myc protein in Jurkat cells is inhibited by hippuristanol 
treatment. Cells were pre-treated with 25µg/ml CHX for two hours to deplete c-Myc 
protein  (lanes  1-2),  and  subsequently  washed  three  times  with  PBS  to  allow  new 
biosynthesis. MG132 was then added at 10µM either alone (lanes 3) or with 25µg/ml 
CHX (lanes 4) or with 1µM hippuristanol  (lanes 5) for two hours. 
 
Contributions: I performed all the experiments for this figure. 
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Figure 3.15 (Continued) 
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Given the fact that c-Myc is hyper-activated in various hematological cancer cell lines 
regardless of their PTEN status, we asked whether translational inhibition of c-Myc via 
eIF4A1 might also be utilized to target c-Myc in those cancer cells. Indeed, application of 
hippuristanol  elicited  robust  inhibition  of  c-Myc  protein  levels  and  tumor  cell 
proliferation in a panel of c-Myc dependent hematological cancer cell lines with normal 
expression of PTEN (Fig 3.16A-3.16D). We further confirmed that in these cells, the 
effect  of  hippuristanol  is  neither  via  transcription  nor  protein  degradation  but  via 
translation (Fig 3. 16E-3. 16G). 
 
Contributions: I performed all the experiments for this figure. 
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Figure  3.16  Hippuristanol,  a  Small  Molecule  Inhibitor  of  elF4A,  Blocks  c-MYC 
Translation in PTEN wt c-MYC Dependent Hematological Cancers 
 
(A) Hippuristanol effectively inhibits cell proliferation of a panel of PTEN-wt, c-MYC-
high T-ALL cell lines with IC50 at nm range. Cells were seeded into 96-well plates and 
hippuristanol was applied at concentration gradients. Seventy-two hours after the drug 
treatment, cell proliferation was measured by MTS assay with IC50s calculated using 
Prism 6.  
 
(B-C) Dose-course (B) and time course (C) of c-MYC abundance inhibition in PTEN wt 
Burkitt lymphoma Daudi cells by hippuristanol. 
 
(D) Hippuristanol effectively inhibits c-MYC protein abundance in a panel of PTEN wt 
c-MYC dependent hematological cancer cell lines. 
 
(E)  The  expression  levels  of  c-Myc  mRNA  in  hematological  cancer  cells  remain 
unchanged upon 1µM hippuristanol treatment at the indicated time points whereas. c-
Myc mRNA levels were measured by quantitative PCR. GAPDH was used as control.  
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Figure 3.16 (Continued) 
 
(F) The de novo synthesis of c-Myc protein in Daudi cells is inhibited by hippuristanol 
treatment. Cells were pre-treated with 25µg/ml CHX for two hours to deplete c-Myc 
protein  (lanes  1-2),  and  subsequently  washed  three  times  with  PBS  to  allow  new 
biosynthesis. MG132 was then added at 10µM either alone (lanes 3) or with 25µg/ml 
CHX (lanes 4) or with 1µM hippuristanol  (lanes 5) for two hours. 
 
(G) Inhibition of eIF4A did not affect c-MYC protein stability. Daudi cells were treated 
with 25µg/ml cycloheximide (CHX) with or without Hippuristanol for the indicated time 
points. Cell lysates were subjected to Western blotting, followed by quantification. 
 
Contributions: I performed all the experiments for this figure. 
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Figure 3.16 (Continued) 
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Discussion and Future Directions 
 
Most cases of T-ALL display upregulated expression of c-MYC, which frequently co-
occurs  with  hyperactivation  of  the  PI3K-AKT  pathway,  often  through  loss  of  PTEN 
(Gutierrez et al., 2009). However, the mechanistic link between the two events in this 
hematological malignancy has not been defined. Using a genetically engineered murine 
model of T-ALL driven by Pten-loss and featuring spontaneous overexpression of c-Myc, 
we found that the abundance of c-Myc protein in this model is critically dependent on 
hyper-activated  PI3K-Akt  signaling.  More  specifically,  we  found  that  the 
PI3K/mTORC1/S6K1  signaling  axis  robustly  regulates  the  translation  of  MYC  via  a 
mechanism which requires the helicase activity of eIF4A to unwind the structured 5’UTR 
of MYC mRNA. 
 
Our current results appear to be in contrast to previous findings from our labs and other 
groups  that  c-MYC  overexpression  renders  cells  resistant  to  PI3K/mTOR  inhibition 
(Clegg et al., 2011; Ilic et al., 2011; Liu et al., 2011). For example, in a murine model of 
breast cancer conditionally expressing human PIK3CA
H1047R, a fraction of the tumors 
which recurred after PIK3CA
H1047R inactivation had focal amplifications of Myc, which 
led to independence of oncogenic PIK3CA and resistance to PI3K inhibition (Liu et al., 
2011). Notably, the focal Myc amplicon in these recurrent tumors identified by a high 
density SNP analysis lacked exon1 of Myc which encodes the Myc 5’UTR (Liu et al., 
2011). Consistently, the c-Myc protein levels in these mammary tumor cells were not 
altered in response to PI3K and eIF4A1 inhibition. Together these findings indicate that   90 
presence  or  absence  of  MYC  5’UTR  may  serve  as  a  biomarker  for  predicting  drug 
responses of c-MYC-dependent tumors to PI3K and eIF4A1 inhibition in human patients. 
 
When activated, mTORC1 is known to regulate a number of translation initiation factors 
that are essential for translation, including eIF4E and eIF4B (Sonenberg and Hinnebusch, 
2009). mTORC1 phoshporylates eIF4E-binding protein (4EBP1), an event that renders 
eIF4E available for binding to eIF4G and consequently, recognition of 5’ cap by the 
eIF4F complex (Sonenberg and Hinnebusch, 2009; Zoncu et al., 2011). Another critical 
downstream factor of mTORC1 is S6K1. Upon activation, S6K1 phosphorylates eIF4B 
on Ser 422 to facilitate the translation initiation (Holz et al., 2005; Raught et al., 2004; 
Shahbazian et al., 2010; Shahbazian et al., 2006). eIF4B is a cofactor of the RNA helicase 
eIF4A  which  is  known  to  be  critical  for  unwinding  structured  5’UTRs.  It  has  been 
previously  shown  that  eIF4A  alone  has  low  helicase  activity  but  its  activity  can  be 
significantly enhanced by binding to the phosphorylated eIF4B (Parsyan et al., 2011). In 
addition, S6K1 phosphorylates and destablizies PDCD4 (Dorrello et al., 2006), an eIF4A-
binding protein that inhibits protein translation (Yang et al., 2003). The involvement of 
PDCD4 in our system remains to be determined.  While both eIF4E and eIF4B have been 
previously implicated in the regulation of c-Myc (Moerke et al., 2007; Shahbazian et al., 
2010), our study demonstrates a robust translational regulation of MYC through the PI3K-
mTORC1-S6K1  signaling  axis  that  activates  the  eIF4B/eIF4A  initiation  complex 
generally in hematologic malignancies dependent on c-MYC overexpression.  
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Aberrant transcriptional overexpression of c-MYC occurs in most cases of both human T-
ALL and murine T-ALL models, often downstream of mutational activation of NOTCH1 
in humans or Myc chromosomal rearrangements in mice (Guo et al., 2008; Guo et al., 
2011; Liu et al., 2010; Weng et al., 2006; Zhang et al., 2011). However, the protein 
abundance of c-MYC is highly variable in T-ALL (Bonnet et al., 2011), suggesting that 
post-transcriptional regulation of c-MYC constitutes a major alternative mechanism of c-
MYC  activation  in  T-ALL.    In  line  with  this,  previous  studies  have  indicated  that 
upregulation of Myc mRNA expression was not sufficient to induce lymphomagenesis 
(Hemann  et  al.,  2005).  It  has  been  proposed  that  c-MYC  protein  abundance  can  be 
modulated by stability of c-MYC via phosphorylation status of T58 regulated by GSK3β 
(Bonnet et al., 2011; Gulati et al., 2008; Zhang et al., 2006). Also, c-MYC transcription 
has been proposed to be regulated by PI3K pathway and MAPK pathway via NFκB 
(Grumont et al., 2002). Here we show that, despite the presence of overexpressed MYC 
transcripts or MYC stabilizing mutations, as found in Burkitt lymphomas (Albert et al., 
1994; Bhatia et al., 1993; Bhatia et al., 1994; Brennscheidt et al., 1994; Johnston et al., 
1991; Yano et al., 1993), PTEN-PI3K dependent de novo synthesis of c-MYC protein is 
essential for sustaining the high abundance of c-MYC protein as well as for proliferation 
of these leukemia cells. Thus PTEN acts like a critical “gatekeeper” on this rate-limiting 
step in c-MYC biosynthesis.  
 
Other than translational and post-translational control, c-MYC transcription also has been 
proposed  to  be  regulated  .  For  example,  the  above-mentioned  post-transcriptional 
regulation of c-MYC by GSK3β and also regulation of c-MYC transcription by    92 
Despite extensive efforts to target c-MYC for cancer therapy, direct inhibition of c-MYC 
protein has so far been unsuccessful (Darnell, 2002). Recent studies in hematological 
cancers  have  revealed  a  novel  strategy  of  targeting  c-MYC  via  suppression  of  its 
transcription through inactivation of BRD4 (Delmore et al., 2011; Mertz et al., 2011). 
These findings suggest that regulating MYC at transcriptional level or other levels may 
result in clinical benefit. Here we demonstrate that inhibition of c-MYC translation can 
also  effectively  suppress  c-MYC  protein  synthesis  and  hematological  tumor  growth, 
providing novel avenues to target undruggable oncogenic lesions via suppression of their 
druggable  regulators.  Numerous  pharmacological  inhibitors  targeting  PI3K,  AKT, 
mTORC1 or S6K1 are already in pre- and clinical development for cancer treatment (Liu 
et  al.,  2009b).    A  number  of  mTOR  inhibitors,  e.g.  rapamycin  and  RAD001,  have 
received FDA approval for clinical use (Lebwohl et al., 2013). Our study suggests that 
these  drugs  could  be  highly  effective  in  treating  T-ALL  patients,  an  idea  with  the 
potential for a fast and meaningful translational outcome.  
 
In  addition,  despite  the  promise  of  Bromodomain  inhibitors  to  suppress  c-MYC 
transcription in various cancer systems, the strategy inevitably has outliers and thus it is 
critical to identify additional potent therapeutical strategies for effectively targeting the c-
MYC oncogene. Here we provide an effective alternative approach to specifically target 
c-MYC translation. It is intriguing to test whether JQ1 can also inhibit c-MYC in outlier 
cell lines which can not be inhibited by hippuristanol thus these two inhibitors can be 
used together to target a larger spectrum of human cancers. 
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Our study might also help explain the effect of the eIF4A inhibitor, hippuristanol, in other 
studies. It has been shown to inhibit the proliferation of HTLV-1-infected T-cell lines and 
ATL cells in vitro (Tsumuraya et al., 2011) as well as to reduce the viability of primary 
effusion lymphoma cells both in vitro and in vivo (Ishikawa et al., 2013). It was also 
reported to sensitize B cell malignancies to chemotherapy (Cencic et al., 2013).  It is 
tempting to speculate these observed effects of hippuristanol might be mediated via the 
translational inhibition of c-MYC. It would be interesting to investigate whether other 
small molecules targeting eIF4A, such as pateamine A (Romo et al., 2000), silvestrol 
(Hwang et al., 2004) and the rocaglamides (Sadlish et al., 2013) can also inhibit c-MYC 
translation  and  whether  targeting  c-MYC  translation  through  eIF4A1  is  applicable  to 
solid tumors as well. 
 
Targeting  translational  components  for  cancer  therapy  has  received  less  attention 
compared  to  other  molecular  targets  critical  for  transcriptional  regulation  or  post-
translational modifications. One of the reasons might be the potential lack of selectivity 
of this approach (Robert and Pelletier, 2009). In the classic model of translational control 
by  mTORC1,  global  translational  regulation  is  achieved  via  phosphorylation  of 
downstream factor 4EBP1, which binds to and inhibits the activity of eIF4E, a more 
general  mechanism  of  translational  control  (Laplante  and  Sabatini,  2012).  Our  study 
suggests that certain oncoproteins, such as c-MYC, contain specific structured 5’UTRs 
and selective targeting may be achievable by inhibiting a less general factor, eIF4A, in 
translational control. We speculate that targeting eIF4A would likely be more specific   94 
and less toxic, especially in tumors such as T-ALL where the MYC transcripts is greatly 
overexpressed. 
 
The effective inhibition of PTEN-deficient hematological malignancies by suppression of 
eIF4A may also provide another therapeutic strategy to target PTEN-deficient tumors. 
PTEN is one of the most frequently deregulated tumor suppressors in various human 
cancers. Despite the large effort to target PTEN-deficient tumors using PI3K inhibitors, 
many PTEN-deficient tumors remain insensitive to PI3K inhibition or develop resistance 
after a short period of exposure (Ilic et al., 2011; Liu et al., 2011; O'Brien et al., 2010; 
Tenbaum et al., 2012). Our findings here demonstrate a promising alternative approach to 
target PTEN-deficient hematological malignancies. It would be interesting to test whether 
eIF4A suppression is effective in PI3K inhibitor insensitive or resistant PTEN-deficient 
hematological cancers.  
 
The fact that hippuristanol is also effective to inhibit PTEN wide type c-MYC dependent 
hematological  cancers  also  suggests  that  the  mechanism  of  eIF4A  regulated  c-MYC 
translation  is  universal  in  hematological  malignancies,  regardless  of  their  PTEN  and 
PI3K signaling status. This could due to in PI3K signaling low cancer cell lines, some 
other upstream signaling such as the RAS signaling, RSK signaling and etc, upregulates 
the signaling to eIF4A. This also means that targeting eIF4A to inhibit c-MYC translation 
is universal in c-MYC dependent hematological malignancies. 
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Taken together, our study has shown a robust regulatory mechanism for the 5’UTR-
dependent translation of MYC mRNA governed by the PI3K/mTORC1-S6K1 pathway 
and has provided conceptual evidence for testing eIF4A as a potential novel target in c-
MYC dependent malignancy. 
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Experimental Procedures 
 
Mice 
 
LckCre  (Hennet  et  al.,  1995)  and  Pten
f/f  (Lesche  et  al.,  2002)  mice  were  crossed
  to 
generate  experimental  mice  for  this  study.  All  animals  were  housed  and  treated  in 
accordance  with  protocols  approved  by  the  Institutional  Animal  Care  and  Use 
Committees at Dana-Farber Cancer Institute and Harvard Medical School. 
 
Cell lines and Culture 
 
Hematological  cancer  cell  lines  were  cultured  in  RPMI  (Life  Technologies) 
supplemented with 10% FBS (Life Technologies) and 1% Pen/Strep (Life Technologies). 
CAMA1  and  T47D  were  cultured  in  DMEM  (Life  Technologies)  supplemented  with 
10%  FBS  and  1%  Pen/Strep.  Primary  cell  lines  were  established  from  isolated 
thymocytes of moribund LckCre
+/Pten
f/f mice and cultured in RPMI supplemented with 
10% FBS and 1% Pen/Strep. 
 
Chemicals  
 
The following small molecule inhibitors were used in this study: BEZ235 (Maira et al., 
2008), BKM120 (Elfiky et al., 2011), MK2206 (Chandarlapaty et al., 2011), RAD001 
(Schuler et al., 1997) and hippuristanol (Bordeleau et al., 2006) were kindly provided by   97 
Novartis Pharmaceuticals. The remaining chemical reagents were purchased from the 
indicated source: PF4708671 (Sigma), Lipofectamine 2000 (Sigma), MG132 (Sigma), 
Cycloheximide  (Sigma),  puromycin  (Sigma),  protease  inhibitor  tablets  (Roche), 
phosphates inhibitor tablets (Roche).  
 
Western Blotting 
 
Cells  were  washed  with  cold  PBS  and  then  lysed  in  1%  Nonidet  P-40  lysis  buffer 
supplemented with protease and phosphatase inhibitors. 15µg of whole cell lysates were 
resolved by SDS-PAGE followed by transfer onto nitrocellulose membrane (Bio-Rad). 
Membranes  were  blocked  and  incubated  with  primary  antibodies  overnight. 
Immunofluorescently  labeled  anti-mouse  IgG  (Rockland  Immunochemicals)  and  anti-
rabbit  IgG  (Molecular  Probes)  were  used  to  develop  band  intensities  in  the  Odyssey 
system (Li-Cor). Quantification of band intensities was performed using Odyssey 3.0 
software. The primary antibodies used for Western blotting in this study were purchased 
from Cell Signaling Technoloy, unless otherwise noted:, c-Myc, Pten, p-AKT (S473), p-
S6RP (S235/236), eIF4A, eIF4B, Actin (Milipore), α-Tubulin (Sigma-Aldrich). 
 
shRNA Constructs and Lenti-viral Infection 
 
shRNAs constructs were purchased from the RNAi Consortium of the Broad Institute. 
Construct sequences are described in Supplemental Table 1. To produce lenti-viruses, 
293T  cells  were  co-transfected  with  shRNA  constructs,  Vsv-g  and  ΔR89  using   98 
Lipofectamine 2000 at the ratio of 5:1:4. Viruses were collected on days 2 and 3 post 
transfection and  one million cells were infected with 1ml virus. Forty-eight hours post 
infection, cells were selected with puromycin at 2ug/ml for two days and then maintained 
in puromycin at 2.5ug/ml. 
 
De deno Synthesis Assay of c-MYC Protein 
 
Cells were pre-treated with 25µg/ml CHX for two hours to deplete c-MYC protein and 
then washed with three times with PBS to allow new biosynthesis. MG132 was then 
added at 10µM either alone or with 25µg/ml CHX, or with inhibitors for one hour to two 
hours.  
 
Retroviral Infections and FACS Sorting 
 
MigR1-MYC T58A construct was a kind gift from Dr. Warren Pear (Abramson Family 
Cancer Research Institute). Human MYC 5’UTR sequence was obtained from NCBI and 
subcloned into MigR1-MYC T58A construct. Primer sequences are as follows: forward, 
5’-ACCCCCGAGCTGTGCTGCTCG-3’  and  reverse  5’-
CGTCGCGGGAGGCTGCTGGTT-3’. pCMV-PTEN was purchased from Addgene and 
subcloned  into  the  MigR1  vector.  With  Lipofectamine  2000  (Life  Technologies), 
retroviruses were generated by co-transfecting 293T cells with MigR1-based plasmids, 
Vsv-g  and  Gag  at  the  ratio  of  5:1:4.  Viruses  were  collected  on  days  2  and  3  post-
transfection and applied to cells. Seventy-two hours post-infection, GFP positive cells   99 
were sorted using BD FACSAria IIu followed by inhibitor treatments or Western blotting 
analysis.  
 
Histology, IHC, Wright-giemsa Staining and White Blood Cell Count 
 
For histology analysis, primary tissues were isolated, fixed with 10% buffered formalin, 
embedded in paraffin, sectioned, and stained with hematoxylin and eosin by the Dana 
Farber/Harvard Cancer Center Rodent Histopathology Core. For IHC, fixed sections were 
dewaxed  and  rehydrated,  boiled  in  citrate  buffer  and  then  blocked.  Antibodies  were 
incubated overnight, and positive nuclei were detected by diaminobenziidine (Sigma). 
Sections were then counterstained with Mayer's hematoxylin. Antibodies used for IHC 
were Ki67 (Vector Laboratories), p-Akt (S473) (Cell Signaling) and p-S6RP (S235/S236) 
(Cell Signaling). For Wright-giemsa staining, cytospin slides (Thermo Scientific) with 
primary  mouse  bone  marrow  cells  and  peripheral  blood  smear  slides  were  stained 
according  to  routine  method  (Lillie,  1944)    using  Wright-giemsa  stain  (Electron 
Microscopy Sciences). Mouse peripheral white blood cell counts were measured using 
HEMAVET Multispecies Hematology Analyzer (Drew Scientific). 
 
Quantitative PCR 
 
Total RNA was extracted from cells using TRIzol reagent (Life Technologies). cDNAs 
were reverse-transcribed using the SuperScript III first strand synthesis kit (Invitrogen) 
and subsequently utilized for quantitative PCR with SYBR Green Master Mix (Applied   100 
Biosystems). Analysis was performed on triplicate PCR data for each biological duplicate 
and  normalized  to  GAPDH.  Primer  sequences  are  as  follows:  MYC  forward,  5’-
CTACCCTCTCAACGACAGCA-3’ and reverse 5’-AGAGCAGAGAATCCGAGGAC-
3’;  Myc  forward,  5’-GTGCTGCATGAGGAGACACC-3’  and  reverse  5’-
TTTGCCTCTTCTCCACAGACA-3’. 
 
In vivo Xenograft and Inhibitor Administration 
 
Five  to  six  week  old  female  C57  Bl/6  recipient  mice  were  purchased  from  Jackson 
Laboratory. A total of two million thymocytes isolated from moribund LckCre
+/Pten
f/f 
mice  were  injected  retro-orbitally  into  sub-lethally  irradiated  recipients.  For  in  vivo 
BEZ235 treatment, BEZ235 was dissolved into one volume of NMP (Sigma) and nine 
volumes  of  PEG300  (Fluka  Analytical)  and  then  gavaged  at  35  mg/kg  mouse  daily 
(Maira  et  al.,  2008),  starting  two  weeks  following  transplantation.  Studies  were 
performed under the auspices of protocols approved by the Institutional Animal Care and 
Use Committees at Dana-Farber Cancer Institute and Harvard Medical School. 
 
Cell Proliferation Assay 
 
Hematological cancer cell lines were seeded onto 96-well plates at a density of 15,000 
cells/well in 100 µl media. CAMA1 and T47D were seeded at 4,000 cells/well in 100 µl 
media and then drugs dissolved in DMSO or DMSO control was added. After seventy-
two hours of incubation, cells were analyzed for cell viability by the addition of 20 µl   101 
/well MTS reagent (Promega). After three hours incubation at 37°C, the signal from the 
viable  cells  was  determined  by  measuring  the  absorbance  at  490nM  on  a  microplate 
spectrophotometer (Bio-Rad). IC50s were calculated using Prism6 (GraphPad). 
 
Luciferase Assay 
 
pGL3-+5’UTR was constructed via inserting the human MYC 5’UTR sequence into the 
pGL3-Basic  (-5’UTR)  (Promega)  firefly  luciferase  reporter  vector.  Cells  were  co-
transfected with pGL3 or pGL3-+5’UTR together with the pRL renilla luciferase reporter 
vector  (Promega)  as  internal  control  at  the  ratio  of  10:1.  Forty-eight  hours  post 
transfection, inhibitors were added to cells for four hours and luciferase activities were 
measured with Dual Luciferase Reporter Assay System (Promega) and detected using 
Lumat LB 9507 (EG&G Berthold). 
 
Statistics 
 
Kaplan-Meier survival curves were constructed using Prism6 (GraphPad), and log-rank 
analysis was used to analyze the results. An unpaired, 2-tail student t-test was used to 
compute P values. 
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Summary 
 
In this thesis, we studied the isoform dependence of PI3K catalytic subunits in PTEN null 
driven T-ALL and found that neither the p110α nor the p110β isoform is critical for its 
tumor maintenance. Study from other groups suggests that the p110δ and p110γ isoforms 
are important for tumorigenesis and tumor maintenance of PTEN null driven T-ALL. 
These  studies  together  demonstrate  the  isoform  specificity  of  PI3Ks  in  leukemia  and 
provided conceptual evidence to develop PI3K isoform specific inhibitors for targeted 
therapy  of  T  cell  leukemias  dependent  on  the  oncogenic  PI3K  signaling.  Given  the 
potential toxicity of using pan-PI3K or AKT inhibitors, isoform specificity studies would 
provide evidence for more specific therapeutics. 
 
Our study also utilized the T cell specific PTEN null mice with spontaneous c-MYC 
over-expression to study potential clinically relevant regulatory mechanism for c-MYC 
expression.  Using  this  model,  we  discovered  that  c-MYC  is  a  critical  downstream 
effector of PI3K signaling in PTEN-deficient hematological malignancy. We found that 
the PI3K pathway controls c-MYC translation via mTORC1/S6K1. S6K1 regulates c-
MYC 5’UTR through the translation initiation factor eIF4A, an RNA helicase critical of 
unwinding  the  structured  5’UTR  of  c-MYC  for  its  translation  initiation.  Importantly, 
either  knock-down  or  pharmacological  suppression  of  eIF4A  by  its  selective 
pharmacological  inhibitor  hippuristanol  robustly  inhibits  c-MYC  translation, 
consequently  markedly  reducing  c-MYC  protein  abundance  and  blocking  tumor  cell 
growth. Our study has thus revealed a clinically relevant regulatory mechanism of c-  105 
MYC translation and provides the rationale for investigating eIF4A as a therapeutic target 
for cancers dependent on c-MYC. 
 
General Discussion and Future Directions 
 
The  results  presented  in  this  thesis  demonstrated  the  significance  to  study  isoform 
specific targeting of PI3K in T-ALL and also showed one novel approach to target c-
MYC dependent hematological cancers via suppression of the PI3K signaling and the 
translation initiation factor eIF4A. These studies provided mechanistic evidence of how 
PI3K signaling induces oncogenic downstream c-MYC protein and how to block c-MYC 
translation for indirect targeting of the undruggable protein.  
 
Several further experiments can be conducted to strengthen the biochemical links in this 
study. First, direct biochemical assays to show that eIF4A interacts with the 5'-UTR of 
Myc and whether the interaction is specific for c-Myc. One critical experiment to address 
this question is to do RNA-ChIP assay. Second, several helicases have by now been 
proposed to act on the 5'-UTR of Myc and it would be important to see that the helicase 
activity of eIF4A has a specific role to unwind the 5'-UTR of Myc. It is plausible to 
conduct in vitro assays showing that blocking helicase activity unloads Myc mRNA but 
not others from the polysomes. Third, to directly prove that PI3K signaling inhibits c-
MYC translation, a protein pulse-labeling followed by immunoprecipitation experiment 
can be conducted. Alternatively, it would be informative to examine the distribution of c-
Myc mRNA on polysome profiles under the same conditions. Fourthly, to prove that the   106 
effect of hippuristanol is indeed on-target effect, mutants of eFI4A that can not be bound 
by hippuristanol can be used to show that the effect of c-MYC inhibition can be rescued. 
In addition, to demonstrate that the phosphorylation of eIF4B by S6K1 is critical for the 
signaling transduction from PI3K to eIF4A, phosphrylation mutant of eIF4B can be used 
to test whether the mutant can cause resistance to PI3K inhibition.  
 
Further physiological experiments also could be conducted for preclinical and clinical 
indications.  For  example,  to  strengthen  the  therapeutical  potential  of  using  eIF4A 
inhibitors for clinical usage, in vivo effect of hippuristanol or eIF4A shRNAs can be 
tested. Also, to validate that the conclusion drawn from human cell lines and mice model 
is  applicable  to  human  patients,  it  is  interesting  to  test  the  effect  of  PI3K  signaling 
inhibitors and eIF4A inhibitor in human patients to check whether they can inhibit human 
patient primary tumor cell line proliferation as well as the c-MYC protein levels. 
 
Another future direction is to check whether the presence or absence of c-MYC 5’UTR in 
hematological cancers is also a biomarker for the response to PI3K and eIF4A inhibitors. 
It is interesting to check whether the mutations in the c-MYC 5’UTR in several cancer 
cell  lines,  such  as  the  Burkitt  lymphoma  cell  lines,  can  cause  resistance  to  eIF4A 
inhibition. If that is the case, it demonstrates that the MYC 5’UTR as well as mutations 
that are important for its function is a critical biomarker for response to PI3K and eIF4A 
inhibition.  
 
One interesting observation is that the inhibition of eIF4E-eIF4G interaction by 4EGI-1   107 
increased c-MYC protein levels in our system. This suggests that the blockage of c-MYC 
cap-dependent translation increased the efficiency of IRES translation, which has been 
suggested for c-MYC. Our preliminary data suggests that adding in the c-MYC 5’UTR 
into the luciferase construct significantly increased its transcription level, suggesting that 
IRES dependent translation is much more efficient than cap-dependent translation in this 
context. And this could be the reason why c-MYC protein level is dependent on eIF4A 
given that its activation is critical for unwinding the c-MYC 5’UTR and expose the IRES 
for more efficient translation machinery. Consistently, for solid tumors less dependent on 
the  c-MYC  oncogene  such  as  breast  cancer  cell  lines,  the  application  of  4EGI-1 
decreased c-MYC levels (Yi et al., 2013), suggesting that cap-dependent translation, the 
less efficient translational machinery, is the main translational machinery for c-MYC in 
c-MYC independent cancers. 
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